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Abstract
The integrated network of biochemical reactions known collectively as metabolism is essential for
life, and dysfunction in parts of this network causes human disease - both rare, inherited disor-
ders and common diseases such as diabetes mellitus. The study of metabolic disease depends
upon quantitative methods which are traditionally custom-tailored to a given compound. Recent
advances in technologies such as mass spectrometry now enable the simultaneous measurement
of a diverse metabolite collection spanning multiple biological pathways, an approach known as
metabolic profiling or metabolomics. This dissertation describes the development of one such
metabolic profiling system and its application to the study of two major topics in human energy
metabolism: the fasting:feeding transition and mitochondrial disease. In the first study, we profile
human plasma in response to glucose ingestion, detecting dozens of metabolite changes and iden-
tifying several distinct effects of insulin. Based on these observations, we propose a multivariate
view of insulin sensitivity, and show that individuals at risk for developing diabetes mellitus can differ
in their insulin response profile, a concept of potential value for estimating disease risk and progres-
sion. In the second study, we elucidate a metabolic signature of human mitochondrial disease that
reflects substrate oxidation, biosynthesis and energy charge. We demonstrate that the culture me-
dia profile of a cellular disease model of mitochondrial dysfunction reflects the plasma profile of
human patients, an approach that could be applicable to other diseases as well. In addition, we
show that a combination of metabolites distinguishes individuals with mitochondrial disease from
healthy individuals better than the currently used diagnostic markers. Our findings provide insight
into human disorders of energy metabolism, and demonstrate the utility of a profiling approach for
the understanding of metabolic disease.
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Chapter 1
Introduction
Introduction
The term Metabolism stands for the collection of chemical reactions by
which living cells extract energy from their environment and convert foodstuffs
into cell components (1). Centuries of research, leading to breakthroughs during
the 2 0th century, uncovered fundamental principles and yielded integrated
theories concerning the thermodynamics, kinetics, and regulation of metabolism
in cells and organisms (1, 2). This knowledge has played an important role in the
understanding of human physiology and disease (3). The description of human
metabolic disorders was pioneered by Sir Archibald Garrod, who coined the term
"inborn error of metabolism" in the beginning of the 2 0th century. Since then
hundreds of such diseases have been described. These rare, inherited disorders,
as well as common, complex diseases with a prominent metabolic component,
such as diabetes mellitus, are collectively known as metabolic diseases.
The study of metabolism and metabolic disease has always depended on
the availability of means to quantify the abundance of molecules. The first
description of an inborn error of metabolism, alkaptonuria, was possible thanks to
the existence of a method for the quantification of homogentisic acid, a
compound whose elevation in urine is the defining feature of this disorder. A
variety of chemical methods for quantitative analysis have been developed and
applied in biological research, though due to the structural diversity of molecules
participating in metabolism each molecule or family of molecules requires a
specialized measurement method. Whereas the uniform structure of nucleic
acids facilitates the use of generic methods for global analysis, enabling the rapid
advancement of genomic technologies and research we see today, the
systematic measurement of metabolites is more challenging.
Metabolic Profiling Technology
Recently, technological advances have enabled the development of
analytical methods that measure many metabolites simultaneously, creating new
opportunities for the study of metabolic disease (4). These advances have also
inspired hopes to measure the entire collection of metabolites in an organism,
which was termed "metabolome" in analogy to the genome. The two main
technologies in this field are nuclear magnetic resonance (NMR) spectroscopy
and mass spectrometry (MS). Methods based on these two technologies can be
either targeted to a pre-defined set of metabolites or untargeted, and can provide
either absolute or relative quantification. This section describes current metabolic
profiling technologies and the types of analytical methods they support.
Nuclear Magnetic Resonance Spectroscopy
In NMR spectroscopy, a magnetic field probes magnetic atomic nuclei
within molecules, eliciting a molecule-specific response and providing information
on molecular structure and abundance. NMR spectroscopy focusing on the
resonance of proton nuclei, known as 'H (proton) NMR spectroscopy, has been
adapted to provide quantitative information on a wide spectrum of metabolites.
Other magnetic nuclei have also been used and provide distinct advantages: 130
spectra are simpler than proton spectra and do not require solvent suppression
(5), while 31P spectroscopy probes phosphate-containing molecules such as
ATP, ADP and phosphocreatine, providing information on the biochemical energy
status in cells and tissues (1). A key advantage of NMR spectroscopy over mass
spectrometry is its non-destructive nature, allowing in vivo studies. The main
disadvantage of NMR spectroscopy is its low sensitivity compared to mass
spectrometry.
Mass Spectrometry
In MS, molecules are ionized and delivered into an electrical field, where
they are distinguished based on their mass:charge (m/z) ratio. A key advantage
of MS is its high sensitivity. A type of mass spectrometer commonly used for
metabolic profiling is the triple quadrupole. A quadrupole consists of 4 circular
rods setup to create a well controlled electrical field. A triple quadrupole mass
spectrometer, also known as a tandem mass spectrometer (or MS/MS), consists
of three quadrupoles arranged in series. The first quadrupole selects ions based
on m/z ratio, the second acts as a collision cell where ions are fragmented, and
the third selects a fragment ion based on m/z ratio (6). MS/MS machines can
simultaneously acquire data on hundreds of precursor-fragment ion pairs, a
technique known as multiple reaction monitoring (MRM). In conjunction with MS,
chromatography is often used to separate between molecular species in a
complex biological sample, delivering them into the mass spectrometer spread
out in time. Both gas chromatography and liquid chromatography have been
used for metabolic profiling. While gas chromatography requires derivatization of
metabolites prior to analysis, liquid chromatography does not impose this
restriction.
Targeted versus Untargeted Analysis
Metabolic profiling methods can be divided into targeted methods and
untargeted ones. Targeted methods quantify a pre-defined set of identified
metabolites, and require the characterization of each targeted metabolite ahead
of time. Untargeted methods, on the other hand, acquire entire spectra, from
which subsequent data processing methods extract distinct features. The
advantage of targeted analysis is that the identity of the measured analytes is
known, which enables biological interpretation of data and helps to avoid
confounding effects. At the same time, non-targeted methods can potentially
detect unexpected metabolites that were not previously considered. Both MS and
NMR spectroscopy can be used in a non-targeted mode, whereas targeted
analysis is done only with MS. Targeted MS analysis is accomplished by the
combination of chromatography and tandem mass spectrometry with multiple
reaction monitoring (6), identifying each metabolite by a unique combination of
chromatographic retention time, precursor ion m/z ratio and fragment ion m/z
ratio. Mass spectrometry technologies that provide a mass resolution high
enough to determine unambiguously the chemical formula of an analyte, such as
Fourier transform ion cyclotron resonance (FTICR) or Orbitrap, can identify
metabolites in an untargeted manner (6). In NMR spectroscopy metabolite
identification is achieved by comparing spectra of biological samples to reference
spectra of pure, individual metabolites (7).
Relative vs. Absolute Quantification
The quantification of metabolites can be absolute, meaning that a molar
concentration is determined for each metabolite, or relative, meaning that
metabolite levels are expressed in arbitrary units. The advantage of absolute
quantification is that the results can be compared to other experiment and to
published literature, whereas relative quantification only allows comparison to
other samples in the same experiment. To obtain absolute quantification, a
metabolite needs to be analyzed over a range of known concentrations, creating
a standard curve that relates abundance readings to molar concentrations. In
mass spectrometry, this is achieved by adding to the biological sample pure
metabolite standards containing one or more stable isotope atoms. An isotope-
containing metabolite co-elutes with the corresponding endogenous metabolite
but its mass/charge ratio is offset by a known number of atomic mass units,
allowing clear separation between the two. The MS ionization efficiency is
molecule-specific, and as a consequence a separate standard curve is required
for each metabolite. Due to the limited availability and high price of isotope-
labeled metabolites, and the amount of labor required, it is usually not feasible to
obtain absolute quantification for a large number of metabolites. Proton NMR
spectroscopy, on the other hand, is much better suited for absolute quantification
since all protons show an identical response factor, regardless of the chemical
properties of the molecules containing them (7).
Human Energy Metabolism
I use the term human energy metabolism broadly to refer to the extraction
of energy from nutrients, its storage and expenditure, on the whole body level
and on the cellular level. In this section I introduce two topics in human energy
metabolism. The first is the transition of the human body from a fasting state to a
fed state and its relation to insulin sensitivity. The second is the dysfunction of
mitochondria, a cellular organelle central to ATP synthesis. While the two topics
are discussed separately in this dissertation, it is important to note that
mitochondrial function affects whole body energy metabolism. Indeed, previous
work has revealed a connection between mitochondrial gene expression and
diabetes mellitus (8).
The Fasting-Feeding Transition and Insulin Sensitivity
The transition of the human body from a fasting state to a fed state
involves multiple organ systems and metabolic pathways (9). During fast, the
body derives energy from food stores, primarily in the form of glycogen and
triacylglycerol, and during a prolonged fast also from protein (10). The liver
breaks down glycogen and releases glucose, while in adipose tissue
triacylglycerol molecules are broken to glycerol and free fatty acids, which are
released to the circulation. Fatty acids are further degraded in the liver to
produce ketone bodies, which support brain function. When glycogen stores are
depleted, alanine derived from muscle protein and lactate derived from glycolysis
in various tissues are used in the liver for gluconeogenesis, in processes known
as the alanine cycle and the Cori cycle. Ingestion and absorption of food triggers
the release of insulin from the pancreas which switches the body from using up
fuel reserves to storing the ingested food as glycogen, lipids and proteins. The
body's ability to switch efficiently is important for future survival in periods of
starvation, and is dependent on the ability of the pancreas to release insulin and
on the sensitivity of the liver, muscle and adipose tissues to the insulin signal.
Diabetes mellitus is a group of metabolic diseases characterized by
hyperglycemia resulting from defects in insulin secretion, insulin action, or both
(11). These diseases affect 8% of the population in the United States according
to a current estimate by the American Diabetes Association. Type 2 (T2DM) is
the most prevalent type of diabetes, characterized primarily by resistance to the
action of insulin. Hepatic insulin resistance results in increased release of
glucose from the liver, whereas resistance in adipose and muscle tissues causes
reduced glucose uptake, all of which contribute to hyperglycemia. During the
early stages of disease progression, pancreatic beta cells attempt to compensate
for the insulin resistance by secreting increased amounts of the hormone, but
after a while their capacity to secrete insulin declines. Chronic diabetes mellitus
is associated with severe complications in eyes, kidneys, the nervous system,
heart and blood vessels (11), causing major health problems. While intense
research efforts aim to elucidate the genetic factors contributing to the
development of T2DM, the pathogenesis of this disease is still not well
understood.
Loss of sensitivity to the action of insulin is an early sign for the
development of T2DM. Insulin sensitivity can be measured directly using the
hyperinsulinemic euglycemic clamp technique (12), in which the rate of glucose
infusion required to maintain constant blood glucose levels under high insulin
conditions reflects the rate of glucose uptake. This technique is difficult to
perform in a clinical setting and is limited to research. Simpler indices of insulin
sensitivity have been developed and compared to the clamp technique (13). The
fasting insulin level is a simple index providing good correlation with clamp-
measured insulin resistance. The homeostasis model assessment (HOMA) of
insulin resistance and beta cell function is based on the combination of fasting
insulin and fasting glucose concentrations (14). Other indices have been
proposed based on time course measurements following glucose ingestion. All
indices of insulin sensitivity are based on the effect of insulin on glucose alone.
While hyperglycemia is the defining feature of diabetes mellitus, insulin has
multiple other physiologic effects, and the action of insulin along these other axes
could provide clinically useful information.
Glucose ingestion after overnight fast is a special case of a fasting-feeding
transition, where the meal consists of glucose only. This physiologic situation has
clinical utility for the diagnosis of diabetes: in the oral glucose tolerance test
(OGTT) an individual ingests 75 grams of glucose after overnight fast, and blood
glucose is measured two hours post-ingestion. A glucose level higher than 140
mg/dl indicates impaired glucose tolerance and a level exceeding 200 mg/dl
indicates diabetes, according to American Diabetes Association guidelines (11).
Metabolic profiling of the human response to a glucose challenge can potentially
describe the spectrum of metabolic processes involved in the fasting-feeding
transition, reveal the multiple physiologic effects of insulin and provide insight into
the pathogenesis of insulin resistance and T2DM. In chapter 3 of this dissertation
I describe the application of a metabolic profiling system to the OGTT in healthy
individuals as well as in individuals with impaired glucose tolerance.
Mitochondrial Dysfunction
Mitochondria play a central role in cellular energy metabolism, performing
the final steps in the oxidation of sugars, fatty acids and amino acids, and using
the released energy to regenerate ATP in a process known as oxidative
phosphorylation (OXPHOS). This process is carried out by the respiratory chain,
a series of five enzymatic complexes embedded in the inner mitochondrial
membrane. The respiratory chain is genetically controlled by two genomes: the
compact mitochondrial DNA (mtDNA) which encodes 13 protein subunits, and
the nucleus which encodes the remaining -77 subunits. The respiratory chain
regenerates ATP by creating a proton gradient across the inner mitochondrial
membrane using complexes I through IV, and coupling the dissipation of this
gradient to ADP phosphorylation by complex V (15). The proton gradient is
created by transporting electrons from the soluble electron carrier NADH and
from various oxidation reactions to oxygen, the final electron acceptor,
simultaneously with removal of protons from the matrix. In addition to their role in
bioenergetics, mitochondria are also involved in other metabolic pathways
involving amino acids, ketone bodies and pyrimidine nucleotides. In addition,
mitochondria also control key regulatory parameters of the cellular environement
including the energy charge and the ratio of [NADH]/[NAD'], which affect various
cellular processes. While it is well recognized that mitochondria have a central
role of in cellular metabolism, a systematic description of the metabolic
alterations caused by mitochondrial dysfunction has not been possible due to the
limitations of traditional analytical methods.
Human mitochondrial disease is broadly defined as a clinically significant
functional failure of the mitochondria. More specifically, the term mitochondrial
disease commonly refers to a primary defect in the respiratory chain. It is
estimated that respiratory chain disease (RCD) affects at least 18.4 in 100,000
people (16) and is the most common group of inborn errors of metabolism (17).
Inherited respiratory chain defects are caused by mutations that reside in the
mtDNA or in the nucleus. The first mutations were discovered in the mtDNA,
following its complete sequencing in 1981 (18). Over 150 different pathogenic
mtDNA mutations and many other rearrangements have been discovered in this
small genome (19). These mutations and rearrangements affect the function of
one or more of the 13 respiratory chain proteins encoded by the mtDNA.
Disease-causing mutations in nuclear genes have been found in structural units
of the respiratory chain, factors necessary for its maturation and assembly,
genes that support the maintenance of mtDNA and genes that control the lipid
composition of the inner mitochondrial membrane (20). Dozens of nuclear genes
underlying RCD have been identified, and have enabled genetic testing for these
disorders. Our group has been successful in the systematic discovery of such
genes through integrative genomics (21-23). While our understanding of the
genetic basis of mitochondrial disease has greatly improved in recent years, the
dual genetic control over the respiratory chain and the multitude of genes and
mutations complicate the molecular diagnosis of this disease.
The diagnosis of RCD is challenging not only due to its genetic basis, but
also because of its variable clinical presentation. The clinical features of
respiratory chain disease span multiple organ systems including the central and
peripheral nervous systems, muscle, eye, blood, endocrine, gastrointestinal,
hearing, kidney and liver (24). For example, a relatively common mitochondrial
syndrome caused by an mtDNA mutation, Mitochondrial Encephalomyopathy,
Lactic Acidosis and Stroke (MELAS), typically affects the central and peripheral
nervous systems, but can also cause cardiomyopathy, diabetes mellitus,
sensorineural hearing loss and intestinal pseudo-obstruction (24). Several
existing methods for the measurement of respiratory chain function help support
the diagnosis. The enzymatic activity of the entire respiratory chain or individual
complexes can be measured in biopsy material, usually muscle. Histochemical
staining of complex IV (Cytochrome c oxidase, COX) and complex II (Succinate
dehydrogenase, SDH) in a muscle biopsy can reveal low COX activity in the
presence of normal SDH activity, indicative of an mtDNA defect. Phosphorous
(31P) NMR can be used to measure ATP and phosphocreatine in muscle or brain
and to test the rate of ATP regeneration in muscle during recovery from exercise.
While these methods provide valuable information, they are either invasive or
require special instrumentation or laboratory techniques. Several diagnostic
algorithms have been proposed for integrating the clinical, biochemical and
molecular findings into a level of certainty in the presence of respiratory chain
disease (25-27), though due to the complexity of these algorithms they are not
commonly used in clinical practice.
The abnormal level of metabolites in biological fluids is an important clue
for the diagnosis of respiratory chain disease. Metabolites are commonly
measured in blood plasma and in urine, and in patients with neurologic
symptoms also in cerebrospinal fluid (28). Respiratory chain dysfunction
decreases the capacity for pyruvate oxidation, and excess pyruvate can be
transaminated to form alanine or reduced to form lactate (29). All three
metabolites are often elevated in respiratory chain disease, and have been
included in diagnostic algorithms (25-27). Lactate, the most commonly used of
the three, is often not elevated in patients with respiratory chain disease, and
may be elevated due to various other causes unrelated to RCD (28). Since
conversion of pyruvate to lactate by lactate dehydrogenase is coupled to the
conversion of NADH to NAD', the molar ratio of [lactate]/[pyruvate] is thought to
reflect the intracellular [NAD']/[NADH] ratio, which is affected by the capability of
the respiratory chain to oxidize NADH (30). Based on this rationale, an elevated
[lactate]/[pyruvate] ratio in biological fluids is used to differentiate respiratory
chain dysfunction from other causes of impaired pyruvate oxidation, such as a
pyruvate dehydrogenase dysfunctional. Elevated intermediates of the
tricarboxylic acid (TCA) cycle have also been proposed as indicative of RCD (31,
32). The elevation of various other organic acids has been linked to respiratory
chain dysfunction, including the dicarboxylic acids adipate, suberate and
sebacate, 3-methylglutaconate, ethylmalonate, 2-ethylhydracylate,
methylsuccinate, and the glycine-conjugated compounds tiglylglycine,
butyrylglycine and isovalerylglycine (31, 32). The association of these
metabolites with respiratory chain dysfunction is based on isolated case reports
and their diagnostic utility is unknown.
The central role of mitochondria in cellular metabolism suggests that
metabolic profiling of mitochondrial dysfunction might identify a diagnostically
useful signature of the disease and help explain its pathogenesis. Chapter 4
describes an investigation of mitochondrial dysfunction in both a cellular model
and in RCD patients.
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Chapter 2
Development of a Mass Spectrometry-Based
Metabolic Profiling System
Development of a Mass Spectrometry-Based
Metabolic Profiling System
In 2005 an initiative at the Broad Institute of MIT and Harvard has begun
aiming to develop a metabolic profiling capability. This collaborative effort
included the selection and purchasing of instruments for liquid
chromatography and tandem mass spectrometry, designating the
metabolites that will be targeted and creating a method for measuring
them, integrating the system with public bioinformatics resources and
evaluating the measurement repeatability. This chapter reviews the
development of a metabolic profiling capability at Broad Institute.
Instrumentation and Metabolite Selection
The core metabolic profiling technology we chose was tandem mass
spectrometry (MS/MS) coupled with high performance liquid chromatography
(HPLC), or in short LC-MS/MS. The main considerations for this choice were the
high sensitivity of modern mass spectrometers, the high metabolite specificity
achievable by the combination of chromatography with molecular fragmentation
and the expertise of the Broad Institute proteomics group in mass spectrometry.
In this setup, a metabolite is identified by the unique combination of three
parameters: chromatographic retention time, the mass/charge ratio of the
precursor ion, and the mass/charge ratio of a major fragment ion. The mass
spectrometer is operated in a "multiple reaction monitoring" mode to
simultaneously quantify all metabolites targeted.
The major instruments comprising this setup (Figure 1) were a triple-
quadrupole mass spectrometer (Applied Biosystems 4000 QTRAP), HPLC
systems (Agilent 1100) and a robotic auto-sampler (LEAP Technologies). To
span a wide biochemical spectrum, we used three different chromatography
columns (provided by Phenomenex) each geared towards a different broad class
of metabolites: Luna Phenyl-Hexyl operating in reversed-phase for amino acids
and amine compounds, Luna Amino operating in normal phase for sugars and
negatively charged compounds such as nucleotides, and Synergi Polar-RP
operating in reversed-phase for polar and acidic compounds such as organic
acids. Additional details on the HPLC and mass spectrometry settings can be
found in Appendix A.
We developed the metabolic profiling system as a multi-purpose resource
for use in various studies of human physiology and disease. Consequently, the
metabolites we targeted for monitoring spanned primary pathways of human
metabolism, including central carbon metabolism (glycolysis, the pentose-
phosphate pathway and the tricarboxylic acid cycle), amino acids and
nucleotides. Lipids and fatty acids were slated for future extension of the
platform, as they require separate extraction and chromatography methods. In its
initial phase, the system was set up to monitor approximately 200 different
metabolites (a complete list can be found in Appendix A). For each targeted
metabolite we purchased a pure standard, tested it on each of the three columns
to select the one providing the best retention and elution parameters, tuned the
fragmentation conditions and identified a major fragment to be monitored.
Computational Integration with Public Resources
A long tradition of biochemistry has created a large body of knowledge of
metabolism scattered in thousands of books and research papers. Efforts for
curation of this knowledge in digital, structured databases (1-4) enable
systematic exploration of relationships between genes, enzymes, reactions and
metabolites. We have interfaced the metabolic profiling system with several of
these databases in order to view our data in the global context of metabolism.
The Kyoto Encyclopedia of Genes and Genomes (KEGG (2)) is a public
database linking between genes, enzymes, reactions, pathways and metabolites
across multiple organisms. We have stored this information in a relational
database and mapped the metabolic profiling system to the database. This
database enabled us to estimate how well we cover the various areas of human
metabolism (Table 1), which helped in planning the inclusion of additional
metabolites. To visualize the coverage of particular biochemical pathways, we
highlighted targeted metabolites on individual KEGG pathway maps (Figure 2).
We have also used this method to visualize experiment results, which assisted in
their interpretation. The metabolic database has also enabled various systematic
analyses such as listing all reactions involving a given metabolite, or all reactions
linking between certain substrate and product metabolites.
With the development of metabolic profiling technologies, metabolite-
centric databases have emerged that provide biochemical information as well as
technical parameters for measurement of metabolites. One such database is the
Human Metabolome Database (HMDB (4)) which aims to document all human
metabolites. We used the biochemical taxonomy of the HMDB to examine the
distribution of metabolites targeted by our system into chemical classes (Figure
3). We have also used the published mass spectra of metabolites included in the
HMDB to propose candidates for unidentified species.
Repeatability of Metabolite Measurement
In the development of analytical methods it is important to estimate
linearity, limits of detection and repeatability (variation). This section describes
the estimation of measurement variation in our metabolic profiling system.
Estimating the variation within a data sample facilitates proper statistical design
of studies that enables detection of meaningful biological effects. Having an
estimate of the variation and knowledge of the expected effect size, one can use
a formal statistical power calculation to determine the number of independent
observations required for a good chance to detect an effect ((5), Figure 4). This
principle applies both to a single analytical assay and to the simultaneous
measurement of hundreds of parameters, as in our metabolic profiling system.
The process of profiling a biological sample encompasses sample
preparation, LC-MS/MS analysis and peak area integration, all of which can
potentially introduce variation. Sample preparation includes multiple steps:
protein precipitation using ethanol, drying of the supernatant and reconstitution in
water for LC-MS/MS analysis (the protocols are detailed in chapters 3 and 4). To
estimate the repeatability of this entire process, we split a single biological
sample into several parts and processed each part separately. We performed
this experiment on the main two types of biological samples we initially targeted -
human plasma and cell culture media. Media was sampled from cultures of
C2C12 mouse myoblasts after 24 hours incubation, allowing the cells time to
effect a change on the media. We calculated the coefficient of variation (CV, the
standard deviation divided by the mean) for each metabolite separately, and
summarized the CV distributions (Figure 5). Metabolites targeted by our system
span a wide range of concentrations in human plasma and in culture media, from
millimolars to micromolars and below. As expected, metabolites with a stronger
signal tended to have lower CVs. The median CV in plasma was 19%, whereas
in culture media the median CV was only 12%. This difference could be due to
the higher mixture complexity of plasma compared to media. The CV distribution
of media sampled from separate culture plates was similar to the distribution of
media sampled from the same plate (Figure 5 panels B and C), indicating that
C2C12 cultures grown under the same conditions have a very similar metabolic
profile.
Figure 1: The metabolic profiling system.
The setup consists of 3 HPLC systems (Agilent 1100) controlling 3 different
chromatographic columns connected to a mass spectrometer (Applied
Biosystems 4000 QTRAP). A robotic arm (LEAP Technologies) automatically
samples from 96-well plates.
Metabolism Area
Amino Acid Metabolism
Nucleotide Metabolism
Carbohydrate Metabolism
Energy Metabolism
Metabolism of Cofactors and Vitamins
Metabolism of Other Amino Acids
Biosynthesis of Secondary Metabolites
Lipid Metabolism
Biodegradation of Xenobiotics
Biosynthesis of Polyketides and
Nonribosomal Peptides
Glycan Biosynthesis and Metabolism
Targeted
79
50
49
35
33
31
23
21
12
Total
370
109
236
80
148
105
114
284
180
Coverage
21%
46%
21%
44%
22%
30%
20%
7%
7%
6 18 33%
4 90 4%
Table 1: Coverage of human metabolites by metabolic profiling
Coverage of human metabolites in the 11 metabolism areas of the KEGG
database (2). Human metabolites were determined based on association with an
enzyme coded by a documented human gene.
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Figure 2: Visualization of metabolite coverage on biochemical pathway
maps.
In this example, the KEGG (2) pathway map for urea cycle and metabolism of
amino groups is shown. Red squares mark metabolites targeted by the metabolic
profiling system.
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Figure 3: Distribution of targeted metabolites into chemical classes.
The chemical classification is based on the chemical taxonomy annotation in the
Human Metabolome Database (4).
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Figure 4: Theoretical calculation of the smallest detectable difference
between two samples as a function of the sample size and the coefficient of
variation (CV).
Based on Student's t-test (assuming two normally-distributed samples) at P=0.05
and a power of 80% (5).
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Figure 5: Reproducibility of metabolite measurement.
The variation associated with sample preparation and LC-MS/MS analysis was
calculated by splitting one sample into several parts and processing each part
separately. The coefficient of variation (the standard deviation divided by the
mean) was calculated for each metabolite detected.
A) Human plasma (n=7).
B) Culture media sampled after 24 hour incubation of C2C12 myoblasts (n=8).
C) Culture media as in panel B, except that samples originated from separate
culture plates (n=8).
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Metabolic profiling of the human response to
a glucose challenge reveals distinct axes of
insulin sensitivity
Glucose ingestion after an overnight fast triggers an insulin-dependent,
homeostatic program that is altered in diabetes. The full spectrum of
biochemical changes associated with this transition is currently unknown.
We have developed a mass spectrometry-based strategy to simultaneously
measure 191 metabolites following glucose ingestion. In two groups of
healthy individuals (n=22 and 25), 18 plasma metabolites changed
reproducibly, including bile acids, urea cycle intermediates, and purine
degradation products, none of which were previously linked to glucose
homeostasis. The metabolite dynamics also revealed insulin's known
actions along four key axes - proteolysis, lipolysis, ketogenesis, and
glycolysis - reflecting a switch from catabolism to anabolism. In pre-
diabetics (n=25), we observed a blunted response in all four axes that
correlated with insulin resistance. Multivariate analysis revealed that
declines in glycerol and leucine/isoleucine (markers of lipolysis and
proteolysis, respectively) jointly provide the strongest predictor of insulin
sensitivity. This observation indicates that some humans are selectively
resistant to insulin's suppression of proteolysis, whereas others, to
insulin's suppression of lipolysis. Our findings lay the groundwork for
using metabolic profiling to define an individual's 'insulin response profile',
which could have value in predicting diabetes, its complications, and in
guiding therapy.
Introduction
Glucose homeostasis is a complex physiologic process involving the
orchestration of multiple organ systems. During an overnight fast, for instance,
glucose levels are maintained through both glycogenolysis and gluconeogenesis,
and the liver begins to generate ketone bodies (e.g., acetoacetate, 3-
hydroxybutyrate) from fatty acids released by adipose tissue (Cahill, 2006).
Ingestion of glucose after overnight fasting then triggers the rapid release of
insulin from the pancreas, which promotes glucose uptake in peripheral tissues
and switches the body from catabolism to anabolism. For example, proteolysis in
skeletal muscle and associated release of amino acids (which support
gluconeogenesis) are replaced by amino acid uptake and protein synthesis
(Felig, 1975; Fukagawa et al., 1985). Also, triacylglycerol lysis in adipose tissue
and hepatic synthesis of ketone bodies are inhibited and replaced by fatty acid
uptake and re-esterification. Hence the transition from fasting to feeding is
accompanied by many changes in metabolite concentrations as the body makes
adjustments to achieve glucose homeostasis.
To obtain a systematic view of the physiologic response to glucose
ingestion in health and disease, we wished to simultaneously monitor the
concentrations of a large and diverse set of metabolites. Such an integrated
analysis can aid in the classification of metabolic states, reveal new pathways,
and potentially improve the sensitivity for detection of abnormalities. Traditionally,
single metabolites or classes of small molecules have been detected using
dedicated analytical assays. With these methods, relationships between diverse
metabolites and pathways have been missed, and a comprehensive picture of a
complex physiologic program has not been possible. Such relationships could, in
principle, be important in understanding disease pathogenesis and in aiding in
the diagnosis of disease.
Recent advances in analytical chemistry and computation now enable the
simultaneous measurement of a large number of metabolites. Two technologies
are commonly used for metabolic profiling: nuclear magnetic resonance (NMR)
spectroscopy and mass spectrometry (MS) (Dunn et al., 2005). While NMR
spectroscopy has a number of advantages, primarily its non-destructive nature,
its ability to provide information on chemical structure and its better suitability for
absolute quantification, it tends to have low sensitivity. MS technology, on the
other hand, affords sensitive and specific analysis of metabolites in complex
biological samples, particularly when implemented as tandem mass spectrometry
and coupled with high performance liquid chromatography (LC), a combination
termed LC-MS/MS. Metabolic profiling with LC-MS/MS technology has already
been successfully used for identifying human plasma markers of myocardial
ischemia (Sabatine et al., 2005) as well as for characterizing the metabolic
response to starvation in model organisms (Brauer et al., 2006).
We have developed an LC-MS/MS metabolic profiling system capable of
quantifying metabolites in plasma (see Methods), and we report here its
application to studying the human response to an oral glucose load. Our system
can measure 191 endogenous human metabolites spanning diverse chemical
classes (Supplementary data 1). This collection of metabolites includes those
previously studied in the context of glucose homeostasis, as well as many
metabolites not previously linked to this area. We first applied this technology to
healthy individuals in order to characterize the normal human response to an oral
glucose challenge, and then asked how this response is affected by reduced
insulin sensitivity in individuals with impaired glucose tolerance.
Results
Eighteen Plasma Metabolites Change Significantly and Reproducibly
during an Oral Glucose Challenge
To systematically characterize the normal biochemical response to
glucose ingestion in humans, we obtained plasma samples for metabolic profiling
from an ongoing study, Metabolic Abnormalities in College Students (MACS, see
Methods). In this study, young adults undergo a series of metabolic evaluations,
including a questionnaire for metabolic syndrome risk factors, indirect
calorimetry, measurement of body composition and a fasting blood lipid profile.
As part of the metabolic assessment, MACS subjects also undergo a 2-hour oral
glucose tolerance test (OGTT) with multiple blood draws. To control for the
fasting condition and for the effects of fluid ingestion, a subset of MACS subjects
selected at random were given an identical volume of water instead of the
glucose solution. Venous blood was drawn during fasting and then every 30
minutes following glucose or water ingestion for the 2-hour duration of the test.
We obtained samples from 22 subjects ingesting glucose and 7 control subjects
ingesting water (Table 1). Serum concentrations of glucose and insulin were
measured throughout the test (Figure 1A). All subjects had normal fasting
glucose levels, and all glucose-ingesting subjects showed normal glucose
tolerance, as currently defined by the American Diabetes Association (American
Diabetes Association, 2007).
We performed LC-MS/MS metabolic profiling of the OGTT time course in
MACS subjects. Out of the 191 metabolites monitored by our platform, 97 were
detected in at least 80% of subjects in all time points (Figure 1B). The levels of
21 metabolites changed significantly (p<0.001) from the fasting levels and were
also significantly (p<0.05) different when compared to the response to water
(Figure 1C). These 21 significantly altered metabolites span pathways previously
studied in the context of glucose homeostasis, as well as some never linked to
this program.
To validate these findings, we profiled fasting and 2-hr OGTT samples
from an independent group. The 2-hr time point has clinical significance, and can
aid in the diagnosis of impaired glucose tolerance and diabetes (American
Diabetes Association, 2007). FOS-NGT (Table 1) is a group of individuals with
normal glucose tolerance, derived from the Framingham Offspring Study (Kannel
et al., 1979). This group is similar to MACS in size, gender composition and
glucose tolerance, but these individuals are approximately 20 years older and
differ in their ancestry (Table 1). Of the 21 metabolites displaying significant
change in MACS at any time-point during OGTT (Figure 1 C), the levels of 20
(glucose excluded) remained significantly (p<0.05) altered at the 2-hour time
point. 18 of these 20 metabolite changes replicated significantly (p<0.05) and in
the same direction in FOS-NGT (Figure 2). The remaining two metabolites,
malate and arginine, fell below our significance threshold. We have thus
identified 18 plasma metabolites exhibiting highly reproducible and likely robust
responses to glucose ingestion in healthy individuals.
Metabolic Profiling Reveals Novel Biochemical Changes During the OGTT
The systematic profiling approach has enabled us to identify a number of
plasma metabolites, not previously associated with glucose homeostasis, that
change reproducibly in response to an oral glucose challenge. Perhaps most
striking were the observed changes in bile acids. The levels of three bile acids -
glycocholic acid, glycochenodeoxycholic acid and taurochenodeoxycholic acid -
more than doubled during the first 30 minutes after glucose ingestion, and
remained elevated for the entire two hours (Figure 3A). Water ingestion
produced a smaller increase in bile acids which was not sustained beyond the 30
minutes time point. All three compounds are primary bile acids conjugated to
glycine or taurine.
The levels of citrulline and ornithine, two non-proteinogenic amino acids
which participate in hepatic urea synthesis, decreased by 35% and 29%
respectively during the 2-hour test (Figure 3B). Gluconeogenesis from amino
acids (primarily alanine), which supports 25-40% of the non glycogen-derived
hepatic glucose output after an overnight fast (Felig, 1975), is coupled to urea
synthesis (Devlin, 2002). The decreases in citrulline and ornithine may thus be
associated with the reduction in gluconeogenesis and urea synthesis following
glucose ingestion.
Hypoxanthine, a purine base generated from degradation of adenine and
guanine nucleotides, decreased in MACS by 39% within two hours of glucose
ingestion (Figure 3C), and this pattern was replicated in FOS-NGT. Xanthine, a
purine base generated from hypoxanthine by oxidation, also decreased in both
groups (MACS: -9%, p<0.05; FOS-NGT: -41%, p<10-4). The decreases in
hypoxanthine and xanthine may be explained by a combination of attenuated
release and accelerated uptake. Hypoxanthine taken up by tissues can support
nucleotide biosynthesis through the purine salvage pathway (Mateos et al., 1987;
Yamaoka et al., 1997) and may also be indicative of a switch from catabolism to
anabolism of nucleic acids, analogous to the simultaneous transitions in fat and
protein metabolism.
Interestingly, hippuric acid increased by over 1000% during the first 30
minutes and decreased gradually thereafter. Most likely this response is not
related to glucose, but rather reflects the presence of the preservative benzoic
acid, a precursor of hippuric acid (Kubota and Ishizaki, 1991), found in the
glucose beverage used for OGTT (see Methods).
Changes in Plasma Metabolites Span Four Arms of Insulin Action
Much of the biochemical response to glucose ingestion, which we studied
in an unbiased way, can be attributed to the broad actions of insulin (Figure 4A).
Specifically, we have detected an increase in lactate and decreases in glycerol,
-hydroxybutyrate and amino acids. These metabolite changes correspond to the
stimulation of glucose metabolism and to the suppression of lipolysis,
ketogenesis and proteolysis (as well as stimulation of amino acid uptake), all of
which are known to be elicited by insulin (Fukagawa et al., 1985; Nurjhan et al.,
1986).
Our method captured the temporal relationship between glucose and
intermediates of glycolysis (Figure 4B). Specifically, the increase of pyruvate,
lactate and alanine occurred between 30 and 60 minutes, lagging -30 minutes
behind the glucose rise, consistent with previous reports (Kelley et al., 1988).
Interestingly, the kinetics of malate, an intermediate in the Krebs cycle, closely
resembled the kinetics of lactate and pyruvate, suggesting that a fraction of the
pyruvate formed through glycolysis was carboxylated to generate malate via
oxaloacetate. To our knowledge, elevation of plasma malate levels due to
glucose ingestion has not been previously reported.
To gain insight into the kinetics of insulin action, we compared temporal
patterns for metabolites indicative of the suppression of fat and protein
catabolism. The levels of glycerol, P-hydroxybutyrate, and multiple amino acids
all declined after glucose ingestion, but the kinetic pattern of glycerol and 3-
hydroxybutyrate was remarkably different from amino acids (Figure 4C). Over
the two hours, the decrease of glycerol and P-hydroxybutyrate levels was 57%
and 55% respectively, while the drop in amino acids was moderate (between 14-
36%). The branched-chain amino acids leucine/isoleucine (indistinguishable by
our method), for example, decreased 33%. Interestingly, the time to reach half-
maximal decrease in the amino acids (50-72 minutes) was greater than in 3-
hydroxybutyrate (42 minutes) and glycerol (30 minutes). Moreover, the inter-
individual variance in metabolite levels shrunk dramatically over the two hours in
glycerol and -hydroxybutyrate (84% and 95% reduction of inter-quartile range,
respectively), while in amino acids the maximal reduction was 53%. These
findings suggest that the suppression of lipolysis and ketogenesis is more
sensitive to the action of insulin compared to suppression of protein catabolism.
Metabolite Excursions Reflect Multiple Dimensions of Insulin Sensitivity
Having identified 18 metabolites that exhibit robust 2-hr excursions, we
were interested in determining whether they might be useful in understanding
insulin sensitivity. Insulin sensitivity is traditionally defined as the ability of insulin
to promote the uptake of glucose into peripheral tissues such as skeletal muscle
and fat or to suppress gluconeogenesis in the liver. A decline of insulin
sensitivity is one of the earliest signs of type 2 diabetes mellitus (T2DM). This
decline is often manifest as elevated levels of fasting insulin, which is strongly
correlated to measurements of insulin sensitivity (Hanson et al., 2000).
Considering that several metabolic processes taking place following glucose
ingestion are mediated by insulin, we hypothesized that insulin sensitivity could
be reflected not only by changes in glucose, but also by the OGTT-response of
multiple other metabolites. Because our initial studies were focused on normal,
healthy individuals spanning a narrow range of fasting insulin levels, we
performed a third analysis on a group of individuals with impaired glucose
tolerance from the Framingham Offspring Study, FOS-IGT, who spanned a
broader range of fasting insulin concentrations (Table 1).
First, to systematically evaluate the relationship between individual
metabolite excursions and fasting insulin, we performed linear regression of the
fasting insulin concentration on each of the 18 2-hr excursions. Out of the 18, six
showed a statistically significant (p<0.05) correlation to fasting insulin, and
included the excursions in lactate, P-hydroxybutyrate, amino acids
(leucine/isoleucine, valine and methionine) and a bile acid (GCDCA) (Table 2).
Taken together with the glycerol excursion, which scored (p=0.07) slightly below
the significance threshold, the response of four distinct insulin action markers
correlated with fasting insulin (Figure 5A). Individuals with high fasting insulin
exhibited a blunted excursion in all seven metabolites: they had a smaller change
both in increasing metabolites (lactate and GCDCA) and in decreasing
metabolites (the other five). Notably, the glucose excursion was not correlated
with fasting insulin (p=0.20). These findings suggest that resistance to the action
of insulin on the metabolism of glucose, fat, and protein is reflected by the
metabolite response to OGTT.
Next, we sought to determine whether a combination of two or more of the
18 metabolite excursions might be more predictive of insulin sensitivity than are
individual excursions. We used forward stepwise linear regression to discover an
optimal linear model relating 2-hr metabolite changes to fasting insulin levels.
The top regression model identified consisted of the excursions in Leu/lle and
glycerol (R2 adj=0.54, p=0.0001). In this bivariate model, the independent
contribution from each metabolite excursion was significant (Leu/lle: p=8x10 -5 ,
glycerol: p=4x10-3 ), and the two predictors were not correlated with each other
(p=0.6). The Leu/lle-glycerol model predicted fasting insulin levels better than
any individual metabolite excursion (Table 2). BMI, which is known to be a strong
predictor of fasting insulin, was less predictive than the bivariate model. Notably,
the explanatory power of the Leu/lle and glycerol excursions was significant even
after controlling for BMI (p=2x10 -3, p=3x10-3 respectively). A graphical
representation of the Leu/lle-glycerol model (Figure 5B) demonstrates that some
individuals with high fasting insulin exhibit a blunted decline in glycerol, while
others exhibit a blunted decline in Leu/lle.
To identify linear combinations of all 18 metabolite excursions that might
be predictive of fasting insulin, we used partial least squares (PLS). PLS is a
multivariate method that finds orthogonal linear combinations (called
components) of the original predictor variables (here, metabolite excursions),
which are most correlated with a response variable (here, fasting insulin). To
determine how many components should be included in the model while keeping
it general, the model is tested on new data (a method called cross-validation). In
the current PLS model, the smallest prediction error was achieved with the first
component alone (Table 2), and a similar error was obtained with the first two
components. Interestingly, the Leu/lle excursion had the largest coefficient in the
first component, while the glycerol excursion contributed primarily to the second.
The prediction error of the bivariate model consisting of the excursions in Leu/lle
and glycerol was lower than the PLS model error (Table 2). These findings
indicate that the excursions in Leu/lle and glycerol are sufficient to capture the
correlation of 2-hr metabolite changes with fasting insulin.
In summary, we have used a univariate approach as well as two
multivariate approaches to investigate the correlates of insulin sensitivity.
Remarkably, all three methods spotlighted the change in Leu/lle and change in
glycerol as being predictive of fasting insulin. Changes in these two metabolites
are blunted in insulin resistant individuals during the OGTT.
Discussion
In the current study, we have applied metabolic profiling to investigate the
kinetics of human plasma biochemicals in response to an oral glucose challenge.
To our knowledge, this is the first study to apply a profiling technology to
characterize this physiologic program. The systematic approach we have taken
has enabled us to recapitulate virtually all known polar metabolite changes
associated with the OGTT, while spotlighting some pathways never linked to this
program. Importantly, simultaneous measurement of multiple metabolites made it
possible to explore connections between metabolic pathways, providing novel
insights into normal physiology and disease.
One of the most surprising findings of this investigation is the dramatic
increase in bile acid levels following glucose ingestion. In response to eating, the
gallbladder contracts and releases bile into the intestines. Bile acids are then
absorbed and travel through the portal vein back to the liver, where the
enterohepatic cycle completes. While the uptake of bile acids to the liver is fairly
efficient, a constant fraction (10-30%) reaches the systemic circulation (Angelin
et al., 1982). In a previous investigation, human subjects ingesting a standard
liquid meal containing fat and protein exhibited an increase of 320-330% in
individual serum bile acids (De Barros et al., 1982). In the current study, we
found that ingesting glucose alone elicits a bile acid response of similar
magnitude (Figure 3A), which is sustained for two hours. Our finding is supported
by previous work showing that glucose ingestion can increase the plasma
concentration of cholecystokinin, a hormone signaling the gallbladder to contract
(Liddle et al., 1985). Interestingly, a recent investigation has shown that bile acids
are a signal for fat and muscle cells to increase their energy expenditure through
activation of thyroid hormone (Watanabe et al., 2006). Given these findings, and
our observation of bile acid release following glucose ingestion, we tested the
hypothesis that bile acids influence peripheral glucose uptake. We could not
detect an effect of bile acids on basal or insulin stimulated glucose uptake,
however, in cultured adipocytes (data not shown). At present the physiologic role
of sustained bile acid release following glucose ingestion is unknown.
Although insulin resistance is traditionally defined as the reduced ability of
insulin to promote glucose uptake or as the impaired suppression of
gluconeogenesis, resistance can emerge in other insulin-dependent processes.
In prior studies, for example, inadequate suppression of lipolysis was observed in
women with a history of gestational diabetes (Chan et al., 1992), and an elevated
proteolysis rate was seen in individuals with HIV-associated insulin resistance
(Reeds et al., 2006). In obesity, manifestations of insulin resistance include
elevated rates of lipolysis (Robertson et al., 1991) and proteolysis (Jensen and
Haymond, 1991; Luzi et al., 1996). We have used metabolic profiling to monitor
insulin action across multiple axes (Figure 4A), and with markers of each axis in
hand, were able to detect kinetic differences between them. In healthy
individuals, insulin's suppression of lipolysis and ketogenesis is rapid compared
to its suppression of proteolysis (Figure 4C), consistent with the different
concentrations of insulin required to inhibit each of these processes (Fukagawa
et al., 1985; Nurjhan et al., 1986). Such differences in the activation thresholds of
metabolic pathways could be contributing to the diversity in the clinical
presentation of insulin resistance. Mouse models of insulin-resistant T2DM
provide another example for inter-pathway differences in insulin sensitivity: in the
livers of these mice, gluconeogenesis is resistant to suppression by insulin, while
lipogenesis is responsive, resulting in hyperglycemia and hypertriglyceridemia
(Brown and Goldstein, 2008). Collectively, these observations demonstrate that
environmental or genetic perturbations could lead to selectivity in insulin
sensitivity and contribute to pathogenesis.
Our study demonstrates that an individual's "insulin response profile",
namely, the vector of sensitivities to insulin action along multiple physiologic
axes, can be revealed by metabolite excursions in response to a glucose
challenge. Specifically, we have shown that excursions in Leu/lle and glycerol,
reflecting the sensitivity of proteolysis and lipolysis to the action of insulin, are
jointly predictive of fasting insulin, with each of the two excursions offering
complementary and significant explanatory power (Figure 5B). These findings
demonstrate that in two individuals, different axes could be responsible for the
same elevation of fasting insulin, and simultaneous measurement of metabolites
can distinguish between the two conditions. Monitoring of the response to
glucose ingestion across multiple axes in larger, prospective clinical studies of
pre-diabetics could establish links between insulin sensitivity profiles and disease
progression, thus helping to predict future diabetes and its complications as well
as to guide therapeutic interventions.
Methods
Human Subjects.
MACS (Metabolic Abnormalitites in College Studnets). Subjects were
young adults in the age range 18-30 who volunteered for the study during the
academic year 2006-7. Control subjects (ingesting water instead of glucose
solution) were assigned at random, balancing gender. Metabolic profiling
analysis was limited to those subjects with normal fasting glucose concentrations
(below 100 mg/dL) and normal glucose tolerance (2-hr glucose concentration
below 140 mg/dL).
FOS (Framingham Offspring Study). Subjects were selected at random
(balancing gender) from among all participants in the fifth FOS examination cycle
(1991-1995) aged 40-49 who had no diabetes mellitus, hypertension or prior
cardiovascular disease. Additional selection criteria for FOS-NGT were normal
fasting glucose concentrations and normal glucose tolerance. Additional
selection criterion for FOS-IGT was impaired glucose tolerance (2-hr glucose
concentration between 140 and 199 mg/dL).
Table 1 lists demographic and metabolic characteristics of groups from the
MACS and FOS studies.
Oral Glucose Tolerance Test.
MACS. Subjects were admitted to the Massachusetts Institute of
Technology Clinical Research Center (CRC) after a 10 hour overnight fast. An
intravenous catheter was inserted into an antecubital vein or a wrist vein and
fasting samples were drawn. Next, each subject ingested a glucose solution
(Trutol, 75 g in 296 ml; NERL Diagnostics, East Providence, RI; contains citric
acid and sodium benzoate) or an identical volume of bottled water (Poland
Spring Water, Wilkes Barre, PA) over a 5 minute period. Additional blood
samples were drawn from the inserted catheter 30, 60, 90 and 120 minutes after
ingestion. Subjects remained at rest throughout the test. The study protocol was
approved by the MIT Committee on the Use of Humans as Experimental
Subjects and the CRC Scientific Advisory Committee.
FOS. Subjects underwent an OGTT as part of the Framingham Offspring
Study (Arnlov et al., 2005). After 12 hour overnight fast, subjects ingested 75g
glucose in solution. Blood samples were drawn fasting and 120 minutes after
glucose ingestion. The study protocol was approved by the Institutional Review
Board at Boston Medical Center.
Metabolic Profiling.
Blood processing. Blood was drawn into EDTA coated tubes. In MACS,
blood was centrifuged for 10 minutes at 60C and 2,000 g. In FOS, blood was
centrifuged for 30 minutes at 40C and 1,950 g. Plasma samples were stored at -
80 0C.
Sample preparation and analysis. Plasma samples were thawed
gradually, and 165 pL from each sample was mixed with 250 pL of ethanol
solution (80% ethanol, 19.9% H20, 0.1% formic acid) to precipitate out proteins.
After 2 hours at 40C, the samples were centrifuged at 15,000 g for 15 minutes,
and 300 pL of the supernatant was extracted and evaporated under nitrogen.
Samples were reconstituted in 60 pL HPLC-grade water, and separated on three
different HPLC columns. The columns were connected in parallel to a triple
quadrupole mass spectrometer (4000 Q Trap, Applied Biosystems) operated in
selected reaction monitoring mode. Each metabolite was identified by a
combination of chromatographic retention time, precursor ion mass and product
ion mass. Metabolite quantification was performed by integrating the peak areas
of product ions using MultiQuant software (Applied Biosystem). Additional details
on the analytical methodology are provided in Supplementary data 1.
Glucose and Insulin.
Plasma glucose concentration was measured with a hexokinase assay
(MACS: Quest Diagnostics, Cambridge, MA. FOS: Abbott Laboratories, IL).
Insulin international units were determined using a radioimmunoassay
(Diagnostic Product Corporation, Los Angeles, CA). In MACS, sodium fluoride -
potassium oxalate blood tubes were used for glucose analysis, and blood tubes
with no additive were used for insulin analysis.
Statistical Analysis.
Univariate analysis. The significance of a change from the fasting
metabolite level was calculated using the paired Wilcoxon signed-rank test. The
significance of a difference between glucose and water ingestion was calculated
using the unpaired Wilcoxon rank sum test. Where all -100 detected metabolites
were tested, a significance threshold of a=0.001 was used to account for multiple
hypotheses testing. A threshold of a=0.05 was used elsewhere.
Multivariate Analysis and Linear Regression. Two multivariate approaches
were used to identify combinations of 2-hr metabolite changes predictive of
fasting insulin: forward stepwise linear regression and partial least squares (PLS)
regression. In stepwise linear regression, the significance threshold for addition
of a variable to the model was a=0.05. In PLS regression, the number of
components to include in the model was determined using leave-one-out cross-
validation. The prediction error of a model was expressed as the root mean
square error of prediction (RMSEP). Missing values (less than 2% of the data)
were replaced with the mean of present values.
Statistical analysis was performed in R (The R Project for Statistical
Computing) and in Matlab (The MathWorks, Inc).
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Figure 1: Temporal response to an oral glucose challenge in individuals
with normal glucose tolerance (MACS).
(A) Kinetics of blood glucose and insulin in response to glucose ingestion (mean
+ s.e.m.).
(B) Magnitude and significance of metabolite change over time. Dots represent
the 97 metabolites detected in plasma. Change is with respect to the fasting
metabolite levels. Significant (p<0.001) changes are colored red.
(C) Significant metabolite changes. 21 metabolites changed significantly
(p<0.001) when compared to their fasting levels and showed a significantly
(p<0.05) distinct response compared to control (water ingestion). Color intensity
reflects the median fold change compared to the fasting levels. Metabolites are
ordered according to the magnitude of change.
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Figure 2: Validation of metabolite changes at the 2-hr time point.
18 out of the 20 metabolites that changed significantly in MACS (Figure 1C)
replicated (p<0.05) in FOS-NGT. Dots correspond to the median fold change of
metabolites at the 2-hr time point. Abbreviations: TCDCA, taurochenodeoxycholic
acid; GCDCA, glycochenodeoxycholic acid; GCA, glycocholic acid, Orn:
ornithine, Cit: citrulline, P-OH-B: P-hydroxybutyrate.
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Figure 3: Metabolic responses not previously linked to glucose
homeostasis.
Kinetic patterns in the MACS group are shown (mean ± s.e.m.).
(A) Bile acids. Abbreviations: TCDCA, Taurochenodeoxycholic acid; GCDCA,
Glycochenodeoxycholic acid; GCA, Glycocholic acid.
(B) Citrulline and ornithine, urea cycle intermediates.
(C) Hypoxanthine, a product of purine nucleotide degradation.
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Figure 4: Metabolites reflecting four axes of insulin action.
(A) Four axes of insulin action and their associated metabolic markers.
(B) The kinetics of glucose and pyruvate derivatives (MACS, mean + s.e.m.).
(C) The kinetics of insulin's suppression of catabolism. Each line corresponds to
one of 12 individual MACS subjects. T1/2: time to half-maximal decrease (median
of all subjects). The inter-quartile range of metabolite levels is shaded in yellow.
Abbreviations: P-OH-B, 1-hydroxybutyrate.
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Figure 5: Correlation between fasting insulin and 2-hr metabolite changes
in individuals with impaired glucose tolerance (FOS-IGT)
(A) 2-hr changes in markers of insulin action are correlated with fasting insulin
concentration. Each dot corresponds to an individual.
(B) A bi-variate model explaining fasting insulin using the 2-hr decline of Leu/lle
and glycerol. Each circle represents an individual, and the circle size is
proportionate to fasting insulin levels. aA representative individual exhibiting a
blunted decline in Leu/lle (resistant to proteolysis suppression). bA representative
individual exhibiting a blunted decline in glycerol (resistant to lipolysis
suppression).
Clinical MACS FOS
Study:
Group: Glucosea Waterb FOS-NGT FOS-IGT
(n=22) (n=7) (n=25) (n=25)
Age 23 ± 3 (18-30) 24 ± 4 (20-30) 45 ± 3 (40-49) 46 ± 3 (40-50)
Gender 9 Y, 13 d 3 Y, 4 ' 13 Y, 12 d 13 9, 12 6
Ancestry Wh:9,As:6,Un:7 Wh:3,Aa:1,As:1,Un:2 Wh:25 Wh:25
BMI 22.4 ± 2.1 22.1 ± 2.7 24.6 ± 3.4 26.8 ± 4.8
(18.3-26.9) (17.8-26.0) (19.0-31.5) (18.8-41.2)
Fasting 78 + 5 77 + 7 89 ± 6 100 + 9
Glucose (71-90) (70-86) (76-100) (87-115)
(mg/dL)
120 min. 86 ± 16 80 ± 9 88 ± 21 153 ± 12
Glucose (66-119) (71-92) (43-122) (140-180)
(mg/dL)
Fasting 4.6 ± 2.9 3.6 ± 0.7 4.2 ± 2.7 10.3 ± 8.1
Insulin (2.8-14.2) (2.8-4.8) (1.0-10.7) (1.0-25.7)
(ulU/mL)
120 min. 18.1 ± 16.5 3.6 ± 1.0 29.7 ± 20.5 102.8 + 51.8
Insulin (3.0-75.9) (2.9-5.5) (1.0-93.3) (35.0-202.3)
(ulU/mL)
IGTI 0/22 N/A 0/25 25/0
NGT c
Quantitative variables are expressed as mean ± s.d. (range).
Abbreviations: MACS, Metabolic Abnormalities in College Students, conducted at
MIT Clinical Research Center; FOS, Framingham Offspring Study; BMI, body
mass index. Ancestry abbreviations: Wh, White; As, Asian; Aa, African American;
Un, Unknown
a Subjects ingesting glucose (OGTT).
b Subjects ingesting water (control).
C Numbers of subjects in each glucose tolerance category. NGT, normal glucose
tolerance; IGT, impaired glucose tolerance (American Diabetes Association,
2007).
Table I: Demographic and Clinical Characteristics of Human Subjects
Predictor(s)
Ab Leucine/Isoleucine
A Valine
A Lactate
A Glycochenodeoxycholic acid
A Methionine
A p-hydroxybutyrate
A Leucine/Isoleucine + A Glycerol c
PLSd
BMI
2R adj
0.36
0.17
0.16
0.14
0.14
0.14
0.54
0.46
0.33
p-value
9E-4
3E-2
3E-2
4E-2
4E-2
4E-2
7E-5
1 E-4
1 E-3
Prediction Errora
6.65
7.74
7.60
7.86
7.68
7.90
5.66
6.89
6.74
a The prediction error is expressed as the root of mean square error of prediction
(RMSEP), in plU/mL insulin.
b A denotes log of the 2-hr fold change of metabolite levels.
C A bivariate model consisting of the 2-hr changes in leucine/isoleucine and in
glycerol
d Partial least squares based on changes in the 18 validated metabolites.
Table II: Regression Models Relating Fasting Insulin to 2-hr Metabolite
Change in Individuals with Impaired Glucose Tolerance (FOS-IGT)
III
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A plasma signature of human mitochondrial
disease revealed through metabolic profiling
of spent cell culture media
Mitochondrial respiratory chain disorders (RCD) are the most common
inborn error of metabolism, but their pathogenesis is poorly understood
and they are notoriously difficult to diagnose owing to their highly variable
clinical presentation and genetic heterogeneity. To rigorously define a
biochemical signature of RCD, we applied mass spectrometry-based
metabolic profiling to both a cellular model of mitochondrial dysfunction
and to the plasma of RCD patients. In cultured myotubes, we found that the
secretion or consumption patterns of 32 metabolites were altered by
inhibition of the mitochondrial respiratory chain. We hypothesized that this
cell culture media-defined panel of metabolites may reflect the biochemical
derangements of plasma from RCD patients. Indeed we found that the
media-defined panel of metabolites strongly discriminated between plasma
of RCD patients (n=17) and healthy individuals (n=25), far better than
random sets of metabolites (P<0.01). Nine of these metabolites accounted
for the bulk of this signal, were concordantly altered in human plasma and
in culture media, and included markers of impaired substrate oxidation
(elevated lactate, alanine, 2-oxoglutarate, succinate, fumarate, malate),
blunted pyrimidine biosynthesis (decreased uridine), reduced energy
charge (elevated creatine), and increased choline. Importantly, a linear
combination of these 9 metabolites discriminated between RCD patients
and healthy controls in a manner superior to and complementary to
currently used plasma markers. Our study provides proof of concept that
profiling spent media from cellular models of disease may provide a
window into the metabolic derangements in plasma, an approach that
could in principle be extended to complex human diseases.
Introduction
The respiratory chain (RC) of mammalian cells comprises a series of five
enzymatic complexes embedded in the inner mitochondrial membrane that
perform oxidative phosphorylation to regenerate adenine triphosphate (ATP).
Respiratory chain activity affects cellular physiology in multiple ways, including
physical coupling to biochemical reactions and control of key regulatory
parameters such as the energy charge and the [NADH]/[NAD'] ratio. In humans,
defects in mitochondrial or nuclear genes that encode respiratory chain proteins,
or factors necessary for its maturation and assembly, lead to respiratory chain
disease (RCD). It is estimated that RCD affects at least 18.4 in 100,000 people
(1) and is the most common group of inborn errors of metabolism (2).
The diagnosis of RCD is challenging owing to its genetic heterogeneity
and variable clinical presentation. A number of diagnostic algorithms have been
proposed (3-5) that integrate clinical, biochemical, histological and molecular
findings. Abnormal concentrations of several metabolites in biological fluids
represent a minimally-invasive component of these algorithms, including the
elevation of lactate, alanine, pyruvate and the lactate/pyruvate ratio. TCA cycle
intermediates have also been proposed as indicative of RCD (6, 7), as well as
various other organic acids, amino acids and acylcarnitines (7, 8), though these
suggestions are based on isolated case reports and have not been incorporated
into diagnostic algorithms. Little information is available on the diagnostic
accuracy of metabolite markers or on the correlation amongst them. Lactate, the
most widely used metabolic marker, unfortunately is often not elevated in RCD
patients, and may be elevated due to various other causes unrelated to RCD (8,
9). A systematic evaluation of metabolic alterations in respiratory chain
dysfunction is needed in order to identify useful diagnostic markers - such
markers could lead to increased accuracy of RCD diagnosis, and may also
reveal the cellular pathways contingent on RC activity.
The extracellular metabolic profile in cell culture provides information on
consumption and secretion of metabolites, and has been previously used as an
innovative method for rapidly classifying yeast mutants that were otherwise
indistinguishable from wild type (10). Inspired by this approach, we hypothesized
that the culture media profile of a cellular RCD model could similarly capture
features of the metabolic derangements in the plasma of RCD patients. This
hypothesis stems from the notion that the net sum of secretion and consumption
by all body cells determines the concentration of metabolites in plasma. We have
recently developed a targeted mass spectrometry method capable of measuring
191 metabolites in biological samples (11, 12). Importantly, this method spans a
wide biochemical spectrum including amino acids and nitrogenous compounds,
organic acids, nucleotides and sugars, enabling simultaneous monitoring of
multiple pathways. Here, we apply this technology to derive an extracellular
profile of RC dysfunction from a cellular model of mitochondrial dysfunction, and
then demonstrate that this panel of metabolites can be utilized to define a plasma
biochemical signature of human RCD.
Results
A Metabolic Signature of RC Dysfunction in a Myotube Culture Model
We induced RC dysfunction in differentiated myotubes using rotenone and
antimycin, potent inhibitors of NADH dehydrogenase (complex I) and
ubiquinol:cytochrome C oxidoreductase (complex III), respectively. We chose
myotubes as a model system due to their high oxygen requirement, and since
myopathy is a frequent manifestation of RCD. The inhibitor concentrations we
used were effective, as apparent from the decrease in the rate of oxygen
consumption (Figure 1A), but did not decrease cell viability even after 24 hours of
drug treatment. We selected the incubation time (8 hours), cell number (5x10 6)
and media volume (10 ml) so as to produce at least a two-fold elevation of lactate
levels in the media compared to the vehicle control (DMSO). At the
concentrations used, rotenone and antimycin elicited comparable effects on
respiratory chain activity, as demonstrated by a similar decrease in oxygen
consumption (Figure 1A) and a similar increase in lactate secretion (Figure 1B).
In the absence of any drug treatment, the levels of 25 metabolites
significantly (p<0.05) changed from fresh to spent media, reflecting consumption
and secretion by cells. We detected the consumption of 8 metabolites, 6 of which
are nutrients provided in the media, including amino acids (serine, tryptophan,
tyrosine, phenylalanine and leucine/isoleucine) and choline. The consumption of
glucose, glutamine and other amino acids was below the significance threshold,
likely due to their high starting concentration in media. We detected the secretion
of 17 metabolites, including amino acids that can be synthesized by mammalian
cells (alanine, asparagine, ornithine, proline, aspartate and glutamate),
nucleosides (cytidine and uridine), tricarboxylic acid (TCA) cycle intermediates
(malate, 2-oxoglutarate, aconitate, succinate and citrate), lactate and creatine.
We next determined which metabolites uptake or release patterns were
significantly influenced by the respiratory chain inhibitors. We found that RC
inhibition altered significantly (p<0.05) the levels of 32 metabolites (Figure 1 B).
Cultures treated with RC inhibitors exhibited faster glucose consumption and
lactate secretion, reflecting acceleration of non-oxidative glucose metabolism
consistent with a dysfunction of mitochondrial ATP synthesis. In contrast, the
uptake of amino acids and choline decreased, suggesting slower biosynthesis of
proteins and membrane lipids, respectively.
We found multiple differences between the antimycin and the rotenone
treatments (Figure 1B). Two metabolites, succinate and uridine, exhibited a
particularly striking discordance between the two inhibitors, being significantly
altered by both but in opposite directions (Figure 1B). Succinate secretion was
strongly enhanced with antimycin but blunted with rotenone. The succinate
pattern, as well as the higher secretion of fumarate and malate with rotenone
compared to antimycin, suggest an opposite effect of the two inhibitors on
succinate dehydrogenase (complex II) activity: whereas antimycin blocks all
enzymes transferring electrons to ubiquinone by preventing its re-oxidation,
rotenone disables only complex I (Figure 1C). It has been previously observed
that complex I inhibition enhances complex II activity, presumably by making a
larger part of the coenzyme Q pool available (13). We can thus explain the
patterns of succinate, fumarate and malate by modulation of complex II activity.
Dihydroorotate dehydrogenase (DHODH), a key enzyme in pyrimidine
biosynthesis, interacts with coenzyme Q similarly to complex 11 (14, 15), and is
therefore expected to be affected by antimycin and rotenone in the same fashion.
Indeed, the secretion of uridine, a product of this pathway, was elevated with
rotenone, possibly reflecting higher activity of DHODH, and decreased with
antimycin, suggesting slower de-novo pyrimidine synthesis (Figure 1C). In
addition, higher dependence on uridine salvage for pyrimidine nucleotide
synthesis could contribute to the lower uridine secretion with antimycin. In
accordance with the media profile, intracellular levels of pyrimidine nucleotides,
but not purine nucleotides, were significantly decreased in the myotube cultures
treated with antimycin (Figure Si). Together, succinate and uridine provide a
metabolic distinction between a "complex I only" dysfunction and an "all
respiratory chain" dysfunction.
Cell Culture-Derived Metabolites Distinguish RCD Patients from Healthy
Controls
To identify biochemical alterations in human RCD, we performed
metabolic profiling on plasma from 16 patients (Table 1) and 25 healthy controls.
All RCD patients had a pathogenic mutation (7 patients) and/or an abnormally
low RC enzyme activity in muscle (11 patients). The cohort included 4 patients
with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke (MELAS, mt
A3243G), 1 patient with Myoclonus, Epilepsy and Ragged-Red Fibers (MERRF,
mt A8344G), 2 patients with mitochondrial DNA (mtDNA) deletions, and one
patient with mtDNA depletion. Muscle involvement was present in all patients,
either as part of the clinical presentation or as a biochemical feature (Table 1).
Plasma was obtained during a routine outpatient visit. We detected 87
metabolites in plasma, including 29 of the 32 metabolites altered in culture
media. Cytidine, inosine and pentose-phosphate were not detected in plasma.
We next asked whether the 29 cell culture-derived metabolites detected in
plasma could distinguish the RCD patients from the healthy controls.
Unsupervised principal component analysis in the space of the 29 model-derived
metabolites showed excellent separation of patients from controls (Figure 2A).
Interestingly, two plasma samples from the same patient (labeled 6.1 and 6.2,
Figure 2A) obtained on two separate visits six months apart were located close
together in the space of the first two principal components, indicating stability of
the metabolic profile. To test whether the separation between patients and
controls was unique to the model-derived metabolite set, we evaluated 1000
other metabolite sets of the same size selected randomly from all metabolites
detected in human plasma. We calculated the discriminatory power of each
metabolite set using linear classification and cross-validation, taking the area
under the receiver operating characteristic (ROC) curve as a measure of
performance. While the average performance with random metabolite sets was
0.87, the model-derived set achieved a performance of 0.98, higher than 99.1%
of all random sets (Figure 2B). The model-derived set ranked similarly high when
performance was expressed as the sensitivity or the specificity. These findings
suggest that the extracellular metabolic profile of RC inhibition in cultured cells
reflects the plasma biochemical profile of RCD patients.
Plasma Markers of RCD
Next we asked which individual metabolite trends are shared between
media of RC-inhibited myotubes and plasma of RCD patients. Nine metabolites
exhibited a significant (p<0.05) difference between RCD patients and controls,
changed significantly in response to myotube inhibition, and showed the same
trend (elevation or decrease) in plasma and in media (Figure 3A). The weights of
these 9 metabolites were among the highest in the linear classifier based on all
29 culture-derived metabolites (Table Sl), and the performance (area under
ROC curve) of a classifier based on the 9 metabolites was 0.96, only slightly
lower than the 29-metabolites classifier (Figure 2B). Thus these 9 metabolites
capture a substantial part of the discriminatory power of the culture-derived
signature. The metabolites that were concordant between the plasma and media
included the expected elevation of lactate and alanine, both of which are part of
current diagnostic algorithms for RCD. This group also included 4 elevated TCA
cycle intermediates: 2-oxoglutarate, succinate, fumarate and malate. The only
metabolite that was decreased in the RCD patients was uridine, whose median
level in RCD patients was 24% lower than the median of controls. Creatine
showed the most striking elevation in RCD patients. To avoid the confounding
effect of oral creatine supplementation, we excluded from the analysis all 5
patients whose medication list at the time of the test included creatine. Still,
median creatine level in RCD patients was 233% higher than the median level in
controls. Finally, choline was 18% elevated in RCD patients. Adjusting for
gender, all 9 metabolites were significantly (p<0.05) different between patients
and controls. We previously reported 21 plasma metabolites that change in
response to glucose ingestion - the only overlapping metabolites are lactate and
malate while the remaining 7 metabolites were measured but not influenced by a
glucose challenge (12).
To assess whether these markers complement each other in
discriminating between RCD patients and controls, we evaluated linear classifiers
based on 3 different metabolite sets: set #1 consisted of lactate and alanine, the
only two metabolites identified here which are currently incorporated into
diagnostic algorithms (3-5); set #2 contained set #1 as well as the 4 TCA cycle
intermediates identified; and set #3 included all 9 metabolites (Table 2). Set #2
achieved higher classification performance than set #1, indicating that TCA cycle
intermediates carry useful information independent of lactate and alanine.
Performance increased further from set #2 to set #3, indicating that the remaining
3 metabolites, uridine, choline and creatine, contain additional independent
information. The same ranking of the 3 sets was observed regardless of the
performance statistic used (area under the ROC curve, sensitivity or specificity).
Discussion
In the current study we have derived an extracellular metabolic profile of
respiratory chain dysfunction from a simple cell culture model of RCD. The use of
a cellular model facilitated a well-powered and well-controlled search for the
metabolic consequences of respiratory chain dysfunction. This enabled us to
focus the subsequent clinical investigation on a smaller number of metabolites
(Figure 1B). The concordance of the 9 plasma markers we identified here (Figure
3) with the trend in culture media provides strong evidence for a mechanistic link
to respiratory chain dysfunction. Our study design was particularly useful given
the limitations of clinical investigations of rare disorders - namely, the relatively
small number of patients in the cohort and the challenges of potential
confounders such as medication usage, diet, and age. Cell culture media
obviously cannot model the complex regulation of metabolite concentrations in
human plasma. Our finding that the cell culture media profile of RC inhibition
recapitulates differences in plasma between patients and controls (Figure 2)
suggests that consumption and secretion patterns in cell culture can capture, at
least in part, the altered metabolic state in RCD patients. This approach could
also be applicable to other metabolic diseases that can be adequately modeled
in cell culture.
At present, the most widely used plasma markers of RCD are lactate,
alanine and pyruvate, all of which reflect impaired pyruvate oxidation. Our results
confirm the expected elevations in plasma lactate and alanine (pyruvate was not
measured), but additionally reveal metabolite changes corresponding to other
pathways that are contingent on the mitochondrial respiratory chain (Figure 3).
The elevation of TCA cycle intermediates in RCD patients likely reflects the
diminished capacity of the RC to oxidize substrates originating from various
pathways that feed into the TCA cycle. While elevated TCA cycle intermediates
have been previously reported in RCD patients, their diagnostic utility when
measured in conjunction with pyruvate oxidation markers has not been
previously evaluated. Our results suggest that these metabolites contain
discriminatory information complementary to lactate and alanine (Table 2). We
have also identified 3 metabolite alterations not previously reported in RCD
patients: high creatine and choline levels, and low uridine. The cellular balance
between creatine and phosphocreatine reflects the capacity to regenerate ATP,
and diminished phosphocreatine concentrations have been detected in the
muscle of patients with mitochondrial myopathy (16). The elevated plasma
creatine detected here could be an extracellular manifestation of the low energy
charge in muscle. We speculate that the elevation of choline could reflect
alterations in phospholipids metabolism.
Uridine is unique among the plasma RCD markers identified here in that it
is the only one decreased (Figure 3). Other plasma metabolites previously
reported to be decreased in RCD patients include citrulline (19) and free carnitine
(20), and though we measured these metabolites in the current study we did not
detect such decreases (N.B. We excluded from analysis patients taking a
carnitine supplement). To our knowledge this is the first report of uridine
deficiency in the plasma of RCD patients. It is notable that cells devoid of mtDNA
require uridine supplementation for survival (17), presumably due to DHODH
dysfunction (Figure 1C). In analogy, the low plasma uridine levels in RCD
patients could indicate higher reliance on salvage of pyrimidines for maintaining
cellular pyrimidine nucleotide levels, as well as less de-novo pyrimidine
synthesis. While in cultured myotubes complex III inhibition diminished the
intracellular pyrimidine nucleotide pools (Figure Sl), it is unknown whether the
same occurs in vivo. Uridine supplementation is beneficial in patients with a
primary defect in the pyrimidine de-novo biosynthesis pathway (18). It is possible
that uridine supplementation could also be beneficial for patients with a uridine
deficiency secondary to RCD.
Genetic lesions of the respiratory chain can affect the entire chain, or a
specific enzymatic complex. Mutations in components of the mitochondrial
translational machinery or in mtDNA maintenance factors affect the entire chain,
while mutations in structural subunits or assembly factors of a particular complex
affect one complex primarily. While histology or biochemical analysis of muscle
biopsy can suggest which complexes are affected, there are currently no
circulating biochemical markers that provide this information. Here, we describe
some striking differences between the complex I and complex III media profiles.
Some of these differences, as in the TCA cycle and pyrimidine biosynthesis
pathways, can be explained at the levels of coenzyme Q and the
dehydrogenases interacting with it (Figure 1C), while for other pathways the
mechanism is presently unknown. Most of the RCD patients studied here had
either a defect in complexes III or IV detected in muscle, or a mutation affecting
the translation of mtDNA-encoded subunits in these complexes. Judging from the
patterns of succinate and uridine, which exhibited a discordance between
complex I and complex III inhibition (Figure 1B), the RCD patients as a group
displayed an "all respiratory chain" dysfunction, with elevated succinate and
decreased uridine (Figure 3), rather than a "complex I only" profile. Metabolic
profiling of genetic RCD models, an example of which has been recently reported
in C. elegans (21), could help delineate the pathogenesis of specific mutations.
Future well-powered studies of human cohorts or genetic models may reveal
genotype-specific metabolic phenotypes, and in particular contrast the "complex I
only" profile with the "all respiratory chain" profile.
In summary, we have reported a plasma biochemical signature of human
RCD, identified through systematic metabolic profiling of a cellular disease
model. The RCD markers identified here reflect multiple pathways contingent on
functional mitochondria, spanning substrate oxidation, biosynthesis and energy
charge. Importantly, we have found that these markers are not redundant but
rather complementary to each other. While our results need to be validated in an
independent study, controlling for potential confounding factors such as
medications, diet and age, the combination of plasma metabolites identified here
could improve the accuracy of minimally-invasive diagnosis of mitochondrial
disease and provide a means for monitoring its progression. Beyond its value for
detecting and monitoring disease, the signature of mitochondrial RCD we report
here provides insight into the pathogenesis of this heterogenous group of human
disorders. Importantly, our report provides a proof of concept that metabolic
profiling of spent media from a cellular model of disease can provide a window
into the metabolic derangements in the plasma of human patients. This
approach may enjoy application to other, even complex metabolic disorders and
could help understand their biochemical pathogenesis.
Materials and Methods
Respiratory Chain Inhibition in Cell Culture
Mouse C2C12 myoblasts were obtained from ATCC and grown in DMEM
(Sigma) containing 4.5g/mL glucose with 10% FBS in 10 cm plates. To induce
myotube differentiation, FBS was replaced with 2% horse serum (Sigma) for 4
days. On the day of the experiment, cultures were placed in 10 mL fresh media in
the presence of 0.1 pM Rotenone (Sigma R8875), 0.5 pM antimycin (Sigma
A8674) or DMSO, and after 8 hours of incubation spent media was sampled for
metabolic profiling. The experiment was done in 8 biological replicates, and 8
samples of fresh media were also obtained for comparison to the spent media.
To prepare media samples for LC-MS/MS analysis, 100 pL of media was mixed
with 100 pL of ethanol solution (80% ethanol, 19.9% water and 0.1% formic
acid). After 20 minutes at 4C, the samples were centrifuged at 15,000 g for 15
minutes and 180 pL of the supernatant was extracted and evaporated under
nitrogen gas. Samples were reconstituted in 60 pL HPLC-grade water and
analyzed.
Cell extract analysis: cell contents were extracted using 1 mL of a methanol
solution (80% methanol, 20% water) at dry ice temperature, after aspirating all
media and quickly washing samples with ice-cold PBS. To prepare extract
samples for LC-MS/MS analysis, the cell suspension was centrifuged at 14,000 g
for 10 minutes and 100 pL of the supernatant was removed and evaporated
under nitrogen gas. Samples were reconstituted in 60 pL HPLC-grade water and
analyzed.
To evaluate the efficacy of respiratory chain inhibitors at the
concentrations used, oxygen consumption rate was measured few minutes
before and after addition of inhibitors or DMSO using a dedicated instrument
(Seahorse Bioscience) as previously described (22). The change in oxygen
consumption was calculated from the ratio of the two measurements.
Cell viability was measured with a calcein assay (Invitrogen C34852) after
24 hours incubation with respiratory chain inhibitors or DMSO.
Human Subjects
The criterion for inclusion of RCD patients in the study was a confirmed
diagnosis of respiratory chain disease, based either on the presence of a
pathogenic mutation or on reduced respiratory chain activity in muscle (Table 1).
Patients were tested during an outpatient visit to the mitochondrial clinic at
Massachusetts General Hospital. 17 blood samples were obtained from 16
patients (one patient tested on two separate visits 6 months apart). Control
subjects were healthy adults participating in an epidemiologic study at
Massachusetts Institute of Technology, selected at random balancing gender.
The control and RCD groups were not matched for age, diet and medications.
The study was approved by the Institutional Review Boards of Massachusetts
General Hospital and Massachusetts Institute of Technology, and informed
consent was obtained from all subjects.
Plasma extraction and preparation for LC-MS/MS analysis was done as
previously described (12). Briefly, venous blood was drawn into an EDTA-coated
tube, centrifuged for 10 minutes at 2,000 g and 6C, and plasma was extracted.
165 pL plasma was mixed with 250 pL ethanol solution (80% ethanol, 19.9%
water and 0.1% formic acid). After 2 hours at 4C, the samples were centrifuged
at 15,000 g for 15 minutes, and 300 pL of the supernatant was extracted and
evaporated under nitrogen. Samples were reconstituted in 60 pL HPLC-grade
water and analyzed.
Metabolic Profiling
Metabolite levels were measured as previously described (12). Briefly,
samples were separated on three different HPLC columns connected in parallel
to a triple quadrupole mass spectrometer (4000 QTRAP, Applied Biosystems)
operated in selected reaction monitoring mode. Each metabolite was identified by
a combination of chromatographic retention time, precursor ion mass, and
product ion mass. Metabolite quantification was performed by integrating the
peak areas of product ions using MultiQuant software (Version 1.1, Applied
Biosystems).
Statistical Analysis
The significance of univariate differences between cell culture conditions
or between healthy and RCD subjects was evaluated using Wilcoxon rank sum
test with a=0.05. Multivariate linear regression was used to calculate the
significance of a metabolite difference between patients and controls adjusting
for covariates such as gender.
Classification
Classification of human subjects based on plasma metabolite levels was
done with the support vector machine algorithm (SVM) using a linear kernel
(Matlab Bioinformatics Toolbox version 3.1, The MathWorks). SVM is designed
to identify a hyperplane that optimally separates two classes, in this case RCD
and Healthy. SVM does not involve inversion of a covariance matrix, and is
therefore unaffected by metabolite co-linearity and does not require
dimensionality reduction. The linear kernel was chosen for simplicity.
Classification performance was estimated based on 100 rounds of cross-
validation. In each round the training set included half the RCD samples and half
the Healthy samples selected by random, and the test set included the remaining
samples. Sensitivity, specificity and area under the receiver operating
characteristic (ROC) curve were calculated based on the test set in each round
of cross-validation, and averaged over all rounds. All classifiers were evaluated
on the same collection of 100 random divisions to training and test parts.
In the comparison of model-derived metabolites to random metabolite sets
(Figure 2B), the distribution of pairwise correlation coefficients amongst the
subset of model-derived metabolites was typical to the superset of metabolites
detected in plasma.
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Figure 1: Metabolic profile of respiratory chain dysfunction in culture
media.
A) Decrease in oxygen consumption following respiratory chain inhibition with
rotenone and antimycin. Oxygen consumption was measured minutes before and
after addition of inhibitors. Data presented as mean ± s.d. (n=3).
B) 32 metabolites significantly (p<0.05) altered with rotenone, antimycin or both
inhibitors. Metabolites are ordered by the degree of change from fresh media in
the control (DMSO) condition. Each condition was tested in 8 biological
replicates.
C) Discordance between complex I and complex III profiles in pathways coupled
to the respiratory chain. Dashed arrows represent electron flow. Red and green
arrows denote trends with rotenone and antimycin, respectively. Abbreviations: I,
complex I; III, complex III; SDH, succinate dehydrogenase (complex II); DHODH,
dihydroorotate dehydrogenase; Q, conenzyme Q; UMP, uridine monophosphate.
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Figure 2: Separation between patients and controls using a metabolic
profile derived from a cellular disease model.
A) Principal component analysis (unsupervised) of plasma samples from RCD
patients (n=17) and healthy controls (n=25), based on metabolites altered in
spent media of the cellular model (Figure 1B). Numbers near red markers denote
patient identifiers (referencing Table 1). 6.1 and 6.2 represent two plasma
samples from patient #6 obtained six months apart.
B) Comparison of the model-derived set of 29 metabolites (arrow) to randomly-
selected sets of the same size. 1000 sets were selected randomly from all 87
metabolites detected in plasma. Multivariate linear classification using the
support vector machine algorithm with cross-validation was used to estimate the
classification performance, expressed as the area under the receiver operating
characteristic (ROC) curve.
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Figure 3: Plasma markers of human RCD.
Nine metabolites that significantly (p<0.05) differ between RCD and healthy
subjects, and are altered in the same direction as in the cellular model (Figure
1 B). Horizontal lines represent group medians.
Age Biochemical Molecular
Gender (yrs) Clinical Presentation Features Diagnosis
c. I,11I,IV, RRF, Large
Chronic progressive external SDH+/COX- mtDNA
1 M 57 ophthalmoplegia and myopathy (muscle) deletion
Exercise intolerance, myopathy,
myoclonus, neuropathy, diabetes,
2 M 54 dysphagia, lipomatosis and SNHL Lactic acidemia mt A8344G
Myopathy, neuropathic pain, exercise c. I (muscle),
3 F 46 intolerance and stroke elevated CK
Multiple
c. I,II,III,IV mtDNA
4 M 62 Encephalomyopathy (muscle) deletions
Muscle cramps, exercise intolerance, TIA
5 F 25 and complex migraine Lactic acidemia mt A3243G
Cerebellar ataxia, dysarthria, peripheral c. I,II,IV
6 F 52 neuropathy and SNHL (muscle)
Headaches, GI dysmotility, hypotonia,
7 F 17 muscle cramps c. I (muscle)
TIA, complex migraine, Crohn's disease,
hearing loss, muscle weakness and
8 F 44 cramps, exercise intolerance. c. III (muscle)
9 F 46 Exercise intolerance, dystonia c. IV (muscle)
Myopathy, chronic headache, sleep
apnea, exercise intolerance, GI
10 M 29 dysmotility c. 1,111 (muscle)
c. I (muscle),
Neurodegenerative encephalopathy with lactic acidemia,
11 F 35 spasticity and involuntary movements elevated CK
Stroke, migraine, SNHL, expressive
12 F 51 aphasia Elevated CK mt A3243G
Myopathy, chronic fatigue, exercise c. Ill,IV
13 M 42 intolerance and hemochromatosis (muscle)
14 F 54 Exercise intolerance, GI dysmotility mt A3243G
Seizures, myoclonus, cardiomyopathy,
15 M 22 mild dementia Lactic acidemia mt A3243G
Myopathy, exercise intolerance, myalgias c. I,III,IV
with fasciculations, SNHL, complex (muscle), mtDNA
16 M 51 migraine and atrial fibrillation elevated CK depletion
Table 1: Demographic, clinical, biochemical and molecular characteristics
of RCD Patients.
Abbreviations: SNHL, sensorineural hearing loss; TIA, transient ischemic attack;
RRF, ragged-red fibers; SDH+/COX-, succinate dehydrogenase positive /
cytochrome C oxidase negative; CK, creatine kinase.
Lactate,
Alanine
+
Lactate, TCA Cycle All 9
Alanine Intermediates Metabolites
Area Under
ROC Curve 0.82 0.92 0.96
Sensitivity1  47% 73% 87%
Specificity2 38% 57% 73%
Sensitivity at 100% specificity
2 Specificity at 100% sensitivity
Table 2: Multivariate classification of plasma from RCD patients and
healthy controls.
Comparison of classifiers based on 3 subsets of the 9 plasma markers identified
(Figure 3). ROC, receiver operating characteristic.
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Chapter 5
Implications and Future Directions
Implications and Future Directions
In 2005 when the metabolic profiling initiative was launched at Broad
Institute, there were few research papers reporting the application of this
technology to mammalian systems. Today, 4 years later, metabolic profiling is a
much better appreciated tool for biomedical research, contributing to the study of
various diseases including cancer (1), cardiovascular disease (2), infectious
diseases (3), diabetes (4-7) and mitochondrial disease. This dissertation
demonstrates the application of metabolic profiling, particularly mass
spectrometry-based, to the study of human physiology and disease. We discuss
here the main implications of this work and some future directions.
Implications
A Multidimensional View of Insulin Sensitivity
Insulin sensitivity is typically defined by the effect of insulin on blood
glucose levels. Our work on the human response to a glucose challenge has
revealed that other axes of insulin action, particularly the suppression of
proteolysis and lipolysis, contain orthogonal information. We postulate that
integrating this information in a multidimensional insulin response profile could
help better characterize insulin resistance in pre-diabetic individuals.
We detected a particularly strong correlation between insulin resistance
and the blunted decrease of branched-chain amino acids (BCAA) following a
glucose challenge. BCAA elevations in obesity, a condition associated with
insulin resistance, have been reported previously (8), and a recent report of
metabolic profiling in obese and lean humans has confirmed this connection (5).
Physiological effects of BCAA have been noted in various aspects of energy
metabolism, including the stimulation of insulin secretion in pancreatic beta cells
(9) and the control of appetite via the mTOR pathway in hypothalamic neurons
(10). It is therefore likely that in the future BCAA will be used clinically as a
marker of insulin resistance.
Novel Findings in the Human Response to a Glucose Challenge
Taking a global profiling approach, we identified physiological effects of
glucose ingestion that were previously unappreciated. These included a striking
increase in plasma bile acids, as well as decreases in the urea cycle
intermediates ornithine and citrulline and in the purine base hypoxanthine. The
strong and sustained elevation of bile acids in response to glucose alone was
surprising, given that fat and protein ingestion are known as the major stimuli for
gallbladder contraction. Since the publication of these results, the elevation of
plasma bile acids in response to glucose ingestion was validated by an
independent group (7). Of particular interest is the reported role of bile acids in
regulating energy metabolism, where they act as a signal for fat and muscle cells
to increase their energy expenditure through activation of thyroid hormone (11).
Taken together, bile acids could be playing a role in glucose homeostasis.
Media Profiling of a Cellular Disease Model for the Identification of a
Disease Signature
In Chapter 4 we have demonstrated the utility of cell culture media
profiling for defining a plasma signature of human mitochondrial disease. Media
profiling of appropriate cellular disease models can help focus the subsequent
clinical investigation on a smaller number of metabolites. This type of study
design is particularly important in the clinical investigation of rare disorders,
where the statistical power is limited by the relatively small number of patients,
and where potential confounding factors may exist. This use of metabolic
profiling technology could simplify the identification of disease markers and
facilitate understanding of pathologic processes in various other conditions,
including common diseases.
A Plasma Signature of Mitochondrial Disease
This dissertation describes the first study of mitochondrial disease to
evaluate such a large number of metabolites. In an unbiased fashion, we have
confirmed previously suggested markers and have identified novel ones,
providing insight into the pathogenesis of these disorders. We have detected
plasma markers reflecting substrate oxidation (lactate, alanine and intermediates
of the tricarboxylic acid cycle), pyrimidine biosynthesis (uridine), energy charge
(creatine) and choline metabolism. We show that a combination of all these
metabolites provides better classification of patients and controls compared to
the currently used markers. Of particular note is the identification of low uridine
levels, suggesting that uridine supplementation might be beneficial to some
patients.
Future Directions
Clinical Interpretation of the Insulin Response Profile
In this dissertation we have proposed the concept of a multidimensional
insulin response profile in pre-diabetic individuals. There is currently no
information on the relationship between an individual's insulin response profile
and disease progression. Prospective clinical studies, in which subjects are
followed over several years, could help explain this relationship. Understanding
which profiles are associated with higher risk of developing diabetes could
improve the medical care of pre-diabetic patients, and delay or prevent the onset
of diabetes.
Validation of the Plasma Signature of Mitochondrial Disease
We have identified here a plasma metabolic signature of mitochondrial
disease. To test the reproducibility of this signature, and in particular the novel
metabolic markers, we are working on the replication of our study in an
independent cohort of patients. We also plan to evaluate the correlation of
markers with disease severity. If such a correlation exists, the signature we have
identified could be very valuable as a marker of disease progression or
therapeutic response.
Physiologic perturbations are useful for unmasking metabolic
abnormalities. The oral glucose tolerance test, for example, challenges the
body's mechanisms of glucose homeostasis and can reveal glucose intolerance.
In a similar fashion, provocative tests in mitochondrial disease patients can
accentuate abnormalities that are difficult to detect at baseline. Exercise
challenges the capacity of muscle mitochondria to oxidize fuel and produce ATP.
In normal individuals, exceeding the mitochondrial capacity leads to elevated
plasma lactate. Exercise also elevates muscle levels of succinate, fumarate and
malate (12). We expect that exercise testing of mitochondrial disease patients
will emphasize some of the abnormalities we have detected at baseline, and
perhaps uncover additional ones.
The Relationship between Genotype and Metabolic Phenotype in
Mitochondrial Dysfunction
Mitochondrial respiratory chain disorders are caused by dozens of
different genes and hundreds of different mutations in either the mitochondrial or
the nuclear DNA. The striking differences between complex I inhibition and
complex III inhibition in the current study suggest that different genotypes could
differ in their metabolic phenotype. An understanding of these differences would
be tremendously helpful for the molecular diagnosis and care of patients. Such
genotype-specific profiles also hold potential for understanding the pathogenesis
of mitochondrial disorders. Future well-powered clinical studies or studies of
genetic models of mitochondrial disease in cells or animals could provide such
insight.
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Supplementary Material:
Metabolic profiling of the human response to
a glucose challenge reveals distinct axes of
insulin sensitivity
Contents:
Item 1: HPLC method
Item 2: Mass spectrometry method
Item 3: Metabolite interferences
Item 4: Reproducibility of metabolite measurement in plasma
Item 5: Chemical classes of monitored metabolites
Item 6: Metabolites reported in the main text
Item 7: Metabolites detected in plasma
Item 8: Metabolites monitored but not detected in plasma
Item 1: HPLC method
Three different HPLC systems were used sequentially in time, and connected to
the mass spectrometer in parallel. All columns were purchased from
Phenomenex (Torrance, CA). The following table lists the parameters of each
HPLC system:
System 1 System 2 System 3
Mobile Phase Aa: A: A:
99.9% water 79.75% water 95% water
0.1% acetic acid 20% acetonitrile 5% acetonitrile
0.25% ammonium 5 mM ammonium
Bb: hydroxide acetate
99.9% acetonitrile 10 mM ammonium
0.1% acetic acid acetate B:
95% acetonitrile
B: 5% water
79.75% 5 mM ammonium
acetonitrile acetate
20% water
0.25% ammonium
hydroxide
10 mM ammonium
acetate
Column Luna phenyl-hexyl Luna Amino Synergi Polar-RP
(4.6x50 mm, 5m) (4.6x50 mm, 5pm) (4.6x50 mm, 4gm)
Gradient From 0%B and 1 From 100%B and From 5%B and 1
mL/min to 90%B 1.5 mL/min to mL/min to 95%B
and 2 mL/min in 0%B and 2.5 and 2 mL/min in
0.7 minutes mL/min in 1.6 2.65 minutes
minutes
Total Run Time
(minutes) 1.4 3.4 3.75
Injection Volume 5 10 10
(JAL)
a A: Aqueous phase
b B: Organic phase.
Item 2: Mass spectrometry method
A Turbo electrospray ionization source was used. The ion spray potentials were
5,000 volt in the positive mode and 4,200 volt in the negative mode. Zero air was
used for the nebulizer and bath gases, and N2 was used for the curtain and
collision gases. The gas pressures used were 50 psi for the nebulizer gas, 60 psi
for the bath gas, 20 psi for the curtain gas and 7 psi for the collision gas. The
bath gas temperature was 400 OC.
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Item 3: Metabolite interferences
The HPLC-MS/MS method was unable to distinguish between a few of the
reported metabolites and other tested metabolites, due to a combination of
isobaric overlap and insufficient chromatographic resolution. Leucine and
isoleucine were indistinguishable, and are therefore always mentioned together
in the text. In the other instances of sets of indistinguishable metabolites, one of
the metabolites in the set was likely to be present in the samples in much higher
concentrations than the rest of the set, based on published concentrations in
human plasma and given the nature of an oral glucose tolerance test. In these
instances, it was assumed that the effect of the non-prevalent metabolites on the
measurement was negligible, and only the prevalent metabolite was reported in
the main text. The sets of indistinguishable metabolites involving a reported
metabolite are listed below, with the prevalent metabolite first: {glucose,
galactose, fructose}, {-hydroxybutyrate, malonate}, and {valine,
guanidinoacetate}.
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Item 4: Reproducibility of metabolite measurement in
plasma
l Detected Metabolites N Reported Metabolites
0.4
0.3
0.2-
0.1
m mI - mI
0-10% 10-20% 20-30% 30-40% 40-50% 50-60%
Coefficient of Variation
60-70% 70-80% Higher
The variation associated with plasma sample preparation and LC-MS/MS
analysis was assessed by splitting one plasma sample into 7 parts and
processing each part separately. The coefficient of variation (CV) equals the
standard deviation of metabolite level divided by the mean metabolite level. The
CV distribution of metabolites reported in the main text (red bars, Item 6 below) is
compared to the distribution of all detected metabolites (blue bars, Item 7 below).
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Item 5: Chemical classes of monitored metabolites
191 Metabolites
i Amino Acids, Nitrogenous
Compounds and Amines
= Purines and Pyrimidines
Organic Acids
Carbohydrates and
Sugar Phosphates
I Vitamins
m Bile Acids
j Phosphate Acids and
Phosphate Alcohols
O Other
The chemical classification is based on the chemical taxonomy annotation in the
Human Metabolome Database (Wishart, D.S. et al. HMDB: the Human
Metabolome Database. Nucleic Acids Res 35, D521-526 (2007).
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Item 6: Metabolites reported in the main text
Standard
Standard Catalog
Metabolite Name Q1a Q3 b DP CEd IPe HPLCf Source Number
Alanine 90.0 44.0 25 15 + 1 Sigma g  A-7627
Arginine 175.1 70.0 25 30 + 1 Sigma A-5131
-hydroxybutyrate 103.0 59.0 -40 -15 - 3 Sigma 54920
Citrulline 174.1 131.0 -50 -15 - 3 Sigma 27510
Glucose 179.1 89.0 -50 -15 - 2 Sigma 49159
Shelton
Scientific -
Glycerol 93.0 57.0 20 21 + 1 IBI IB15762
Glycochenodeoxycholi Sigma
c acid 448.3 74.0 -80 -60 - 3 G0759
Glycocholic acid 464.3 74.0 -30 -60 - 3 Sigma G2878
Hippuric acid 178.1 134.0 -50 -16 - 3 Sigma 112003
Histidine 156.1 110.0 25 23 + 1 Sigma H-8125
Hypoxanthine 135.0 92.0 -50 -23 - 3 Sigma 56700
Isoleucine 132.1 86.0 50 20 + 1 Sigma 1-2752
Lactate 89.0 43.0 -40 -20 - 2 Sigma 69771
Leucine 132.1 86.0 50 20 + 1 Sigma L-8000
Lysine 147.1 84.0 25 25 + 1 Sigma G-3126
Malate 133.0 115.0 -40 -20 - 3 Sigma M-0750
Methionine 150.1 61.0 40 30 + 1 Sigma M-9625
Ornithine 133.1 70.0 40 30 + 1 Sigma 75480
Phenylalanine 166.1 120.0 50 17 + 1 Sigma P-2126
Pyruvate 87.0 43.0 -30 -12 - 3 Sigma 107360
Taurochenodeoxycholi Sigma
c acid 498.3 80.0 -90 -90 - 3 86335
Tyrosine 182.1 136.5 25 17 + 1 Sigma T-3754
Valine 118.1 72.0 25 20 + 1 Sigma V-0500
Xanthine 151.0 108.0 -40 -30 - 2 Sigma 95490
a QI: precursor ion mass, in daltons (Da)
b Q3: product ion mass, in daltons (Da)
c DP: De-clustering Potential, in volts (V)
d CE: Collision Energy, in volts (V)
e IP: Ionization Polarity
f HPLC: the HPLC system in which the metabolite was measured. See the HPLC
section (Item 1 above) for the parameters of each system.
g Sigma: Sigma-Aldrich Co.
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Item 7: Metabolites detected in plasma
(metabolite #1-97)
Column description:
KEGG: Compound ID from the Kyoto Encyclopedia of Genes and Genomes,
http://www.genome.ad.jp
Q1: precursor ion mass, in daltons (Da)
Q3: product ion mass, in daltons (Da)
HPLC: the HPLC system in which the metabolite was measured
CV: Coefficient of variation of plasma sample analysis
The name used for a metabolite in the main text is in square brackets
(if different from KEGG)
# KEGG Name Q1 Q3 HPLC CV
1 C001089 (R)-3-Hydroxybutanoate [0-hydroxybutyrate] 103.0 59.0 3 27
2 C00186 (S)-Lactate [Lactate] 89.0 43.0 2 7
3 C00149 (S)-Malate [Malate] 133.0 115.0 3 32
C00026/
4 C06104 2-Oxoglutarate/Adipate 145.1 101.0 3 20
5 C00632 3-Hydroxyanthranilate 154.0 136.2 1 54
6 C00197 3-Phospho-D-glycerate 185.0 97.0 2 78
7 C01015 4-Hydroxy-L-proline 132.1 86.2 1 15
8 C00847 4-Pyridoxate 182.1 138.0 3 15
9 C01996 Acetylcholine 146.1 87.0 1 18
10 0C00008 ADP 426.0 79.0 2 66
11 001551 Allantoin 159.0 116.0 1 13
12 C00020 AMP 346.1 79.0 2 85
13 0C00108 Anthranilate 138.0 120.0 1 18
14 0C00002 ATP 506.0 159.0 3 34
15 0C00719 Betaine 118.1 58.0 1 14
16 0C00486 Bilirubin 583.3 285.0 3 69
17 0C00114 Choline 104.1 60.0 1 18
18 0C00417 cis-Aconitate 173.0 129.0 3 32
C00158/
19 0C00311 Citrate/Isocitrate 191.0 111.0 3
20 0C00300 Creatine 132.1 90.0 1 16
21 0C00791 Creatinine 114.1 44.0 1 14
C01094/
C00085/ D-Fructose 6-phosphate/D-Glucose 1-
C00103/ phosphate/alpha-D-Glucose 6-phosphate/D-
22 C00668 Fructose 1-phosphate 259.0 97.0 2 18
23 0C00191 D-Glucuronate 193.0 113.0 3 27
C00117/
24 0C00199 D-Ribose 5-phosphate/D-Ribulose 5-phosphate 229.0 97.0 3 33
25 C00365 dUMP 307.0 79.0 3 29
C00122/
26 0C01384 Fumarate/Maleate 115.0 71.0 2 18
27 C00035 GDP 442.0 79.0 3 34
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28 0C00341 Geranyl diphosphate 313.1 79.1 3 46
C00031/
29 C00124 Glucose 179.1 89.0 2 8
30 C00116 Glycerol 93.0 57.0 1 5
31 C00111 Glycerone phosphate 169.0 97.0 3 35
32 0C05466 Glycochenodeoxycholate [GCDCA] 448.3 74.0 3 16
33 0C01921 Glycocholate [GCA] 464.3 74.0 3 15
34 C00044 GTP 522.0 159.0 3
35 0C01586 Hippurate [Hippuric acid] 178.1 134.0 3 24
36 0C00544 Homogentisate 167.0 123.0 3 30
37 0C00262 Hypoxanthine 135.0 92.0 3 19
38 0C00130 IMP 347.0 79.0 2 18
39 0C00294 Inosine 267.1 135.0 3 30
40 0C00956 L-2-Aminoadipate 160.1 116.0 2 33
41 0C00243 Lactose 341.1 161.0 2 8
42 0C00041 L-Alanine [Alanine] 90.0 44.0 1 16
43 0C00062 L-Arginine [Arginine] 175.1 70.0 1 13
44 0C00152 L-Asparagine 133.1 74.0 1 14
45 C00049 L-Aspartate 134.0 74.0 1 15
46 C00327 L-Citrulline [Citrulline] 174.1 131.0 3 30
47 0C00097 L-Cysteine 122.0 76.0 1 27
C00407/
48 0C00123 Leucine/Isoleucine 132.1 86.2 1 8
49 C00025 L-Glutamate 148.1 84.0 1 19
50 0C00064 L-Glutamine 147.1 84.0 1 14
51 0C00135 L-Histidine [Histidine] 156.1 110.0 1 14
52 0C00155 L-Homocysteine 136.0 90.0 1 17
53 0C00328 L-Kynurenine 207.1 144.0 3 16
54 0C00047 L-Lysine [Lysine] 147.1 84.0 1 15
55 0C00073 L-Methionine [Methionine] 150.1 61.0 1 34
56 C00077 L-Ornithine [Ornithine] 133.1 70.0 1 17
57 0C00079 L-Phenylalanine [Phenylalanine] 166.1 120.2 1 6
58 0C00148 L-Proline 116.1 70.0 1 11
59 0C00065 L-Serine 106.0 60.0 1 19
60 C00188 L-Threonine 120.1 74.0 1 18
61 0C00078 L-Tryptophan 205.1 188.3 1 3
62 0C00082 L-Tyrosine [Tyrosine] 182.1 136.3 1 7
63 C02170 Methylmalonate 117.0 73.0 2
64 C03406 N-(L-Arginino)succinate 291.1 70.0 1 46
65 0C01026 N,N-Dimethylglycine 104.1 58.0 1 19
66 0C00003 NAD+ 662.1 540.0 2
67 C03626 NG,NG-Dimethyl-L-arginine (asymmetric) 201.1 156.0 3 36
68 C03626 NG,NG-Dimethyl-L-arginine (asymmetric/symmetric) 203.1 70.3 1 36
69 Not found NG,NG-Dimethyl-L-arginine (symmetric) 201.1 131.0 3
70 C03884 Ngamma-Monomethyl-L-arginine 189.1 70.0 1
71 0C00153 Nicotinamide 123.0 80.0 1 13
72 0C00295 Orotate 155.0 111.0 3 31
73 C01103 Orotidine 5'-phosphate 367.0 323.1 2
74 0C00209 Oxalate 89.0 61.0 3 33
75 C00036 Oxaloacetate 131.0 87.0 3 24
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76 C00127 Oxidized glutathione 611.2 306.0 2
77 C00864 Pantothenate 218.1 88.0 3 46
78 C00166 Phenylpyruvate 163.0 91.0 2 29
79 C03722 Pyridine-2,3-dicarboxylate 166.0 122.0 2 25
80 C00314 Pyridoxine 170.1 152.2 1 7
81 C00022 Pyruvate 87.0 43.0 3
82 C00780 Serotonin 177.1 160.0 1 25
83 0C00093 sn-Glycerol 3-phosphate 171.0 79.0 2 9
84 C00042 Succinate 117.0 73.0 3 33
85 C00245 Taurine 126.0 108.0 1 14
86 005465 Taurochenodeoxycholate [TCDCA] 498.3 80.0 3 17
87 0C00068 Thiamin diphosphate 423.0 303.2 2 9
88 C01104 Trimethylamine N-oxide 76.1 58.0 1 19
89 0C00015 UDP 403.0 79.0 3 36
C00029/
90 0C00052 UDPglucose/UDP-D-galactose 565.1 323.0 2 132
91 Not found Unidentified peak 149.0 87.0 3 26
92 C00106 Uracil 111.0 42.0 2 24
93 C00366 Urate 167.0 124.0 3 24
94 0C00299 Uridine 243.1 110.0 2 16
95 0C00075 UTP 483.0 159.0 3
C00183/
96 0C00581 Valine 118.1 72.0 1 7
97 C00385 Xanthine 151.0 108.0 2 11
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Item 8: Metabolites monitored, not detected in plasma
(metabolite #98-191)
Column description:
KEGG: Compound ID from the Kyoto Encyclopedia of Genes and Genomes,
http://www.genome.ad.jp
Q1: precursor ion mass, in daltons (Da)
Q3: product ion mass, in daltons (Da)
HPLC: the HPLC system in which the metabolite was measured
# KEGG Name Q1 Q3 HPLC
98 C00631 2-Phospho-D-glycerate 185.0 79.1 3
99 C01179 3-(4-Hydroxyphenyl)pyruvate 179.0 107.0 3
100 C00575 3',5'-Cyclic AMP 328.1 134.0 2
101 C00942 3',5'-Cyclic GMP 344.0 150.0 3
102 0C05145 3-Aminoisobutanoate 104.1 86.0 1
103 C03227 3-Hydroxy-L-kynurenine 223.1 162.0 3
104 C05594 3-Methoxy-4-hydroxyphenylethyleneglyco 183.1 150.0 2
105 Not found 3-Nitro-L-tyrosine 227.1 181.3 1
106 C02642 3-Ureidopropionate 133.1 115.0 1
107 0C00334 4-Aminobutanoate 104.1 87.0 1
108 0C00156 4-Hydroxybenzoate 137.0 93.0 3
109 C03479 5-Formyltetrahydrofolate 472.2 315.0 2
110 C005635 5-Hydroxyindoleacetate 190.1 146.0 2
111 C00643 5-Hydroxy-L-tryptophan 221.1 204.0 1
112 C00440 5-Methyltetrahydrofolate 458.2 329.0 2
113 0C00164 Acetoacetate 101.0 57.0 2
114 0C00024 Acetyl-CoA 403.6 79.0 3
115 C00147 Adenine 134.1 107.0 2
116 C00212 Adenosine 266.1 134.0 2
117 C03794 Adenylosuccinate 462.1 79.0 3
118 0C00072 Ascorbate 175.0 115.0 3
119 0C00120 Biotin 243.1 200.0 2
120 0C00487 Carnitine 163.1 85.0 1
121 0C00386 Carnosine 227.1 110.0 1
122 C00112 CDP 402.0 158.9 3
123 C02528 Chenodeoxycholate 391.3 373.5 2
124 0C00695 Cholate 407.3 343.0 3
125 0C00055 CMP 322.1 79.0 2
126 Not found Cotinine 177.1 80.0 1
127 0C00063 CTP 482.0 159.0 3
128 C02823 Cyanocobalamin 678.3 147.3 1
129 Not found Cystamine 153.0 108.0 1
130 0C01678 Cysteamine 78.0 61.0 1
131 C00475 Cytidine 244.1 112.0 1
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C00380/
132 C00388 Cytosine/Histamine 112.0 95.0 1
133 C00705 dCDP 386.0 79.0 3
134 C00239 dCMP 306.1 79.0 3
135 0C00458 dCTP 466.0 159.0 3
136 C00559 Deoxyadenosine 252.1 136.3 1
137 0C00881 Deoxycytidine 228.1 73.0 1
138 0C00526 Deoxyuridine 229.1 113.0 1
139 C00095 D-Fructose 179.1 89.0 2
C005378/
C00665/ D-Fructose 1,6-bisphosphate/D-Fructose 2,6-
140 1C00660 bisphosphate/D-Glucose 1,6-bisphosphate 339.0 79.0 3
141 000577 D-Glyceraldehyde 89.0 59.0 2
142 0C00415 Dihydrofolate 442.2 176.0 2
143 C03758 Dopamine 154.1 137.2 1
144 000794 D-Sorbitol 181.1 89.0 2
145 0C00364 dTMP 321.1 195.0 3
146 0C00459 dTTP 481.0 383.0 3
147 0C00460 dUTP 467.0 370.0 3
148 C05589 Epinephrine/Normetanephrine 184.1 166.3 1
149 0C00346 Ethanolamine phosphate 142.0 44.0 1
150 C00504 Folate 440.1 311.0 3
151 0C00051 Glutathione 306.1 143.0 2
152 0C00037 Glycine 76.0 30.5 1
153 0C00144 GMP 362.1 79.0 3
154 0C00242 Guanine 150.0 133.0 2
155 0C00387 Guanosine 282.1 150.1 2
156 001817 Homocystine 267.1 132.0 3
157 C05582 Homovanillate 181.1 137.1 2
158 0C01717 Kynurenate 188.0 144.0 2
159 0C01724 Lanosterol 425.4 212.1 2
160 C02291 L-Cystathionine 221.1 134.0 3
161 0C00263 L-Homoserine 120.1 74.2 1
162 C05588 L-Metanephrine 198.1 180.5 1
163 C05589 L-Normetanephrine 184.1 134.0 1
164 0C00083 Malonyl-CoA 425.6 79.0 3
165 C01598 Melatonin 233.1 174.3 1
166 Not found Methylhydroxyisobutyrate 119.1 87.0 1
167 C00137 myo-Inositol 179.1 81.0 2
168 0C00004 NADH 664.1 408.0 2
169 0C00006 NADP+ 742.1 620.0 2
170 000005 NADPH 744.1 408.0 2
171 0C05926 Neopterin 252.1 192.0 2
172 C00253 Nicotinate 122.0 78.0 3
173 0C01185 Nicotinate D-ribonucleotide 334.0 290.0 2
174 C05127 N-Methylhistamine 126.1 109.0 1
175 0C00074 Phosphoenolpyruvate 167.0 79.0 2
176 000163 Propanoate 73.0 55.0 3
177 0C00584 Prostaglandin E2 351.2 315.3 3
178 0C00018 Pyridoxal phosphate 246.0 97.0 3
179 0C00021 S-Adenosyl-L-homocysteine 385.1 136.3 1
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180 C07588 Salicyluric acid 194.1 150.0 3
181 C00315 Spermidine 146.2 72.0 1
182 0C00750 Spermine 203.2 129.3 1
183 0C00089 Sucrose 341.1 179.0 3
184 005122 Taurocholate 514.3 123.8 3
185 C00214 Thymidine 243.1 127.0 1
186 0C00178 Thymine 125.0 42.0 2
187 000167 UDPglucuronate 579.0 403.0 2
188 C00105 UMP 323.0 79.0 3
189 0C01762 Xanthosine 285.1 153.0 1
190 0C00655 Xanthosine 5'-phosphate 363.0 79.0 3
191 C02470 Xanthurenic acid 204.0 160.0 2
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Figure SI: Intracellular levels of nucleotides in myotubes treated with RC
inhibitors.
Levels of purine and pyrimidine nucleotides were measured in cell extract
following 8 hours of inhibition with rotenone or antimycin, and compared to
treatment with vehicle (DMSO). Data is presented as mean + s.d. over 8
biological replicates per condition.
* denotes p-value < 0.05.
Abbreviations: ATP, adenine triphosphate; GTP, guanine triphosphate; CTP,
cytidine triphosphate; UTP, uridine triphosphate.
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411
Metabolite
Succinate
Choline
2-Oxoglutarate
Xanthine
Creatine
Alanine
Citrate
Glucose
Fumarate
Ornithine
Lactate
Uridine
Serine
Tyrosine
Betaine
Arginine
Glycerol
Dimethylglycine
Phenylalanine
Methionine
Malate
Quinolinate
Aconitate
Tryptophan
Proline
Asparagine
Aspartate
ADMA/SDMA
Glycerol 3-
phosphate
Table Sl: Metabolite weights in a linear classifier of RCD patients and
controls based on the cell culture-derived metabolic profile.
The 29 metabolites are ordered by decreasing weight. In bold: the 9 metabolites
which were significant in both media and plasma and concordant between the
two systems (Figure 3). For each metabolite, its median weight over 100 cross-
validation rounds is presented.
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% of Total
Weight
8.7
8.4
6.4
6.3
6.2
6.0
6.0
5.9
5.9
5.4
5.1
4.7
4.7
4.1
2.7
2.3
2.0
1.8
1.6
1.6
1.4
0.8
0.7
0.5
0.4
0.2
0.1
0.1
Sign
+
+
-
+
+
-
+
+
+
+
-
-
+
-
-
-
+
+
+
-
-
--
0.0
7
